Covid-19 will pass. What about the racism it has illuminated? – STAT

The Covid-19 pandemic is teaching me that the world can change almost overnight when it faces a big problem.

When President Trump declared a national emergency, my medical practice shifted almost instantly from in-person appointments to telehealth visits. The Drug Enforcement Administration allowed doctors like me to prescribe buprenorphine, a controlled substance used to combat opioid addiction, after a telephone consult, a move experts have been seeking for years. The Department of Health and Human Services waived privacy constraints for telehealth visits, which have long tied up this type of medicine, allowing doctors to use commonly available platforms like FaceTime, Facebook Messenger, Skype, and Zoom to provide medical care.

And Congress quickly passed the CARES Act, a $2 trillion aid package to fight Covid-19 that included sending $1,200 checks to individuals and families who were most vulnerable to job loss and other financial stressors.

advertisement

As a psychiatrist who treats opioid addiction and works at a minority-serving hospital, I am delighted by these long-sought changes. But I am also frustrated that they have happened so quickly. Frustrated because the U.S. has been facing an equally large and equally deadly problem racism for years and has done little to address it.

Black people are dying at alarming and disproportionate rates from Covid-19. In cities, the statistics are nothing short of tragic. In Chicago, for example, 70% of coronavirus deaths are among Black people, who make up only 30% of the citys population. A similar pattern is seen in other cities and counties across the country.

advertisement

Black and brown people have been seeking reparations to address the systemic injustices they have faced for decades. Yet there has never been an economic stimulus to address the impact of racism on health, quality of life, and advancement.

The countrys response to the new coronavirus does, however, suggest that we are taking steps toward addressing the damaging threat of racism.

First, though, we have to name it. Policy leaders across the country urged Trump to declare a national emergency because they understood the power of naming a crisis. In the same way, we need to declare that racism is a national emergency. It is a virus in the truest sense: a corrupting influence that spreads through communities and across the nation. Systemic racism has harmed and killed millions of Americans through its corruption of health care, criminal justice, and the economic marketplace.

Dr. Deborah Birx, who serves as the coronavirus response coordinator for the White House coronavirus task force, recently suggested that Black people are dying of Covid-19 at higher rates due to underlying medical conditions. She is right if she means that the underlying condition is racism, not its manifestations like high blood pressure and diabetes. Racism has created inequality in access to health care, housing, wealth, education, and employment, all of which undermine health. It is time to name racism as the crisis it is.

Second, we must shift policy to address the circumstances of those affected by the crisis. For Covid-19, that means finding unique ways to care for patients. To address racism, we must do that and go even further. We must not only come up with new ways to reach patients who have been disadvantaged but must also address the dire circumstances that racism has created.

The first time I ever used telehealth was after Covid-19 had emerged as a nationwide threat. My patient, who was homeless, had been sitting in a park all day, waiting for my call. He knew if we didnt connect, he would not be able to get the medication he needed to help him stay free from using heroin. He adjusted his life to meet health cares demands. Thats not the way health care should be it should meet patients where they are and address the circumstances they are in.

During that call, I didnt stick to my usual script: Any problems filling your prescription? Any medication side effects? Any cravings or heroin use since the last visit? Instead, I talked with him about the challenges he was facing at the shelter. He asked about how to manage his day since he couldnt stay inside. I also let him know where he could find a hot meal on a daily basis.

I wish our health care system would take a similar approach and see value in working on problems like housing and food insecurity. Some are calling this concept structurally competent care; it needs to become our new normal.

Third, we must deal with the economic consequences of the crisis. For Covid-19, thats the thrust of the CARES Act. In Boston, where I completed my medical training, the median net worth of white families was more than $200,000. The median net worth of black families was $8. Undoing racism means passing something like the CARES Act to provide funds for those disadvantaged by racism.

I respect Dr. Anthony Fauci, a key member of the White House coronavirus task force, who acknowledged the role of health disparities in Covid-19. He has said that we must deal with these issues once we get beyond the pandemic.

But I disagree with him on that. We must deal with them now.

Morgan Medlock, M.D., is an assistant professor of psychiatry at Howard University College of Medicine in Washington D.C. and the editor of Racism and Psychiatry: Contemporary Issues and Interventions (Springer, 2019)

See the rest here:

Covid-19 will pass. What about the racism it has illuminated? - STAT

Infection Rate May Indicate a Future Diagnosis of Cancer – Cancer Network

In an article published inCancer Immunology Research, researchers suggested that immune suppression and increased infection could occur during the precancerous period.1

However, cancer can occur through a lifespan, therefore the authors indicated that further research is necessary to clarify these precancer trends.

"Cancer can develop in an inflammatory environment caused by infections, immunity disruption, exposure to chemical carcinogens, or chronic or genetic conditions,"co-author of the study Shinako Inaida, PhD, a visiting researcher at the Graduate School of Medicine at Kyoto University in Japan, said in a press release.2"An individual's immunity is thought to be a factor in the development of cancer, but additional research is needed to understand the relationship among precancerous immunity, infections, and cancer development.

In this 7-year case-control study of people 30 years of age, researchers looked to determine the prevalence of influenza, gastroenteritis, hepatitis, and pneumonia infections to indirectly assess whether infections correlated to the formation of malignant cancer. Using data extracted from a large medical claims database of a Japanese social health insurance system, researchers identified 2,354 people with their first cancer diagnosis occurring in the seventh year of the study for the case group and 48,395 people with no cancer diagnosis by the seventh year of the study for the control group.

The most common cancers diagnosed in the case group were digestive and gastrointestinal, head and neck, and stomach cancers. Other cancer types diagnosed in the case group included cancers within the following categories:

The yearly prevalence rates of influenza, gastroenteritis, hepatitis, and pneumonia infections were found to increase throughout the study period, with the case group experiencing higher rates of infection compared to the control group. Moreover, age-adjusted odds ratios (OR) and 95% confidence intervals (CI) in cases 1 year before cancer detection were significantly higher. During this year, the infection prevalence rates for the case group were higher than the control group by 18% for influenza (OR, 1.29; 95% CI, 1.14-1.46), 46.1% for gastroenteritis (OR. 1.60; 95% CI, 1.41-1.82), 232.1% for hepatitis (OR, 3.38; 95% CI, 2.12-5.37), and 135.9% for pneumonia (OR, 2.36; 95% CI, 1.79-3.13).

In patients with influenza infections, significant ORs were found only in the second and sixth years before cancer diagnosis. Further, for each cancer site, an increased rate of infection prior to cancer diagnosis was observed.

The researchers also found that certain infections appeared to have a greater correlation with specific cancer types. For example, the odds of influenza infection just before cancer detection were highest for those who developed male germ cell cancers. Additionally, the odds of pneumonia were found to be highest in those who later developed stomach cancer and the odds of hepatitis infection were highest in those who developed hematologic, blood, bone, or bone marrow cancers.

"Interestingly, we found that infection afflicting a specific organ did not necessarily correlate with increased risk of cancer in the same organ," Inaida explained.

Notably, the researchers only extracted the first cancer diagnosis for each patient and given that the observation period was limited to 8 years, further cancer diagnoses may have been missed. The data also did not include information such as the grade or stage of tumors, which may have been important to estimating each precancerous period.

Another limitation highlighted by the researchers was that patients with infection who did not visit the hospital may have been overlooked. Moreover, influenza vaccination status may prevent infection, although a patient's influenza vaccination record was not available in for this dataset.

Patients who feel unwell, potentially because of cancerous status, tend to see doctors more often, the authors wrote. Although our study considered four major infections, analysis of other infections and the timing of infection before malignant cancer detection, which can potentially be a factor for later cancer development, remains to be studied.

References:

1. Inaida S, Matsuno S. Previous Infection Positively Correlates to the Tumor Incidence Rate of Patients with Cancer.Cancer Immunology Research.doi:10.1158/2326-6066.CIR-19.0510.

2. Increased rate of infections may indicate a future cancer diagnosis [news release]. American Association for Cancer Research. Published April 17, 2020. eurekalert.org/pub_releases/2020-04/aafc-iro041520.php. Accessed April 17, 2020.

More:

Infection Rate May Indicate a Future Diagnosis of Cancer - Cancer Network

Misleading coronavirus information falsely attributed to Johns Hopkins – AFP Factcheck

Social media posts attribute a list of points about the novel coronavirus to Johns Hopkins, a leading source of information on the virus. But the US universitys medical program said it is not the source of the claims, and while some are accurate, experts say others contain false or misleading information.

EYE-OPENING KNOWLEDGE FROM John Hopkins University, says one of the posts, variations of which have circulated on Facebook since at least March 23, 2020.

Others attribute the claims to Irene Ken, a physician whose daughter is an Asst. Prof in Infectious Disease at Johns Hopkins University, or to a Prof in infectious diseases at Johns Hopkins University, or to John Hopkins Hospital.

The points also appear on Reddit here and here, while versions have been posted on Instagram here, here and here.

Johns Hopkins is tracking the spread of COVID-19 -- the disease caused by the novel coronavirus -- providing statistics on deaths and infections as well as other information for both policymakers and the public, meaning its name lends authority to those who cite it.

But Johns Hopkins Medicine said it is not affiliated with the points circulating online, posting on its Facebook page that rumors and misinformation like this can easily circulate in communities during a crisis.

The rumors that we have seen in greater volumes are those citing a Johns Hopkins immunologist and infectious disease expert. We do not know the origin of these rumors and they lack credibility, it said.

And "we have no information" on whether Irene Ken or her daughter exist, a spokesperson for Johns Hopkins Medicine said.

Some of the points themselves are also problematic. AFP Fact Check breaks them down below.

Claim: The virus is not a living organism, but a protein molecule (DNA) covered by a protective layer of lipid (fat), which, when absorbed by the cells of the ocular, nasal or buccal mucosa, changes their genetic code. (mutation) and convert them into aggressor and multiplier cells.

Several parts of this description are false, experts say.

The coronavirus arrives as an RNA molecule that comes wrapped in lipid and protein -- the first point is complete nonsense as written, Dr. Benjamin Neuman, an expert in coronaviruses who chairs the Biological Sciences department at Texas A&M University-Texarkana, told AFP by email.

There are no aggressor or multiplier cells -- not sure what that might even be referring to, he said.

Dr. Julian Leibowitz, an expert in coronaviruses who is a professor of microbial pathogenesis and immunology at Texas A&M's College of Medicine, agreed.

This is not true on many levels. The virus is an RNA virus, it contains no DNA, and its RNA genome is encased in a protein and is then enveloped by a lipid bilayer that contains several viral proteins, he said by email.

When the virus infects cells the virus RNA expresses its genes, it does NOT mutate the genes of the host to convert them into aggressor and multiplier cells, Leibowitz said.

Claim: Since the virus is not a living organism but a protein molecule, it is not killed, but decays on its own. The disintegration time depends on the temperature, humidity and type of material where it lies.

This point is accurate, according to Dr. Wendy Keitel, professor of molecular virology and microbiology at Baylor College of Medicine.

As mentioned, the decay or loss of the viruses ability to infect does depend on temperature, humidity and the type of material where it lies, she said by email.

Claim: The virus is very fragile; the only thing that protects it is a thin outer layer of fat. That is why any soap or detergent is the best remedy, because the foam CUTS the FAT (that is why you have to rub so much: for 20 seconds or more, to make a lot of foam). By dissolving the fat layer, the protein molecule disperses and breaks down on its own.

Some viruses are very fragile; others are not fragile at all, said Keitel, with coronaviruses being significantly less stable than smallpox, for example.

Soap or detergent is a very effective way to help remove viruses from hands, she said, but while the detergent is important for removing soil and may have some effect on inactivation of the virus, the major effects are friction (rubbing the surfaces) and rinsing off the viruses.

Claim: HEAT melts fat; this is why it is so good to use water above 77 degrees Fahrenheit for washing hands, clothes and everything. In addition, hot water makes more foam and that makes it even more useful.

This point is misleading; while the virus is sensitive to heat, Keitel said that it is likely that a temperature high enough to inactivate coronavirus would be too hot for handwashing.

Hands can be washed in warm or cold water as long as the use of soap and the duration of cleansing is at least 20 seconds, she said.

Neumen said that there are proteins in the coronavirus that do indeed denature with heat, but the virus is used to growing in human lungs and intestines, and it is stable up to temperatures a little above 100 degrees F.

He also highlighted issues with the points information about heat melting fat.

There are fats that melt at different temperatures -- for example, bacteria that live in methane ice and bacteria that live on the rims of... deep ocean volcanoes both have membranes made of lipid molecules (what this person is calling fat), but they have very different melting points, Neuman said.

Claim: Alcohol or any mixture with alcohol over 65% DISSOLVES ANY FAT, especially the external lipid layer of the virus.

This is not too far off from reality, Neuman said.

Keitel agreed: Alcohol is believed to destroy the essential viral proteins and may disrupt the lipid (fatty) layer that is part of the coat.

Claim: Any mix with 1 part bleach and 5 parts water directly dissolves the protein, breaks it down from the inside.

This is true, but excessive, according to Neuman.

A standard store-bought hypochlorite bleach will indeed kill the virus, but it works at half the specified concentration, he said.

Claim: Oxygenated water helps long after soap, alcohol and chlorine, because peroxide dissolves the virus protein, but you have to use it pure and it hurts your skin.

This is false.

The amount of oxygen dissolved in water would have very little effect on the virus. This suggests some kind of sham medical product to oxygenate water for health benefits, Neuman said.

Leibowitz agreed: Oxygenated water does not generate hydrogen peroxide and alcohol kills the virus after one minute of exposure.

Claim: NO BACTERICIDE OR ANTIBIOTIC WORKS. The virus is not a living organism like bacteria; antibiotics cannot kill what is not alive.

This is true, unless it is a product also aimed at viruses.

Many products are both bactericidal and virucidal (destroying both, physically), but it is correct that a specific bactericide would not be effective, according to Neuman.

Antibiotics generally do not inactivate viruses; hence, treatment of a viral infection with a common antibiotic would not be expected to inactivate the virus, and it could cause harmful side effects, Keitel said, while also noting that a number of disinfecting chemicals have both antibacterial and antiviral activities.

Claim: NEVER shake used or unused clothing, sheets or cloth. While the virus is glued to a porous surface, it is very inert and disintegrates between 3 hours (fabric and porous), 4 hours (copper and wood), 24 hours (cardboard), 42 hours (metal) and 72 hours (plastic). But if you shake it or use a feather duster, the virus molecules float in the air for up to 3 hours, and can lodge in your nose.

The recommendation is accurateif the items in question are contaminated with the virus.

The current public health recommendations at this time are to avoid shaking contaminated materials due to the theoretical possibility that the contaminated surfaces could release infectious material, said Keitel.

If your feather duster is covered in large amounts of SARS-CoV-2, then I would agree -- don't shake it. Otherwise, it's fine to dust as usual, Neuman said, using the official name for the novel coronavirus.

And Leibowitz said that the numbers mentioned in this point are not quite right.

The virus can survive for at least 8 days on metal (steel) or hard plastic at room temperature but the relative survival on cardboard, paper, or fabric is relatively short and about 3 hours is the number I have seen, he said.

Claim: The virus molecules remain very stable in external cold, or artificial as air conditioners in houses and cars. It also needs moisture to stay stable, and especially darkness. Therefore, dehumidified, dry, warm and bright environments will degrade it faster.

Neuman said the virus does not do well in any of the environments mentioned.

It remains stable almost indefinitely in a specialized -80 degree Celsius freezer, but tends to fall apart eventually at any higher temperature including a regular -20 degree Celsius home freezer, he said.

And according to Leibowitz, the relationship between humidity and virus survival shows that it is less stable at both high and very low humidity but it was most stable at 20% humidity, which is actually pretty low. Cold increases survival time.

Claim: UV LIGHT on any object that may contain it and break down the virus protein. For example, to disinfect and reuse a mask is perfect. Be careful, it also breaks down collagen (which is protein) in the skin.

UV light can inactivate viruses, but Keitel said it is not recommended for the general public to use this method.

At this time it is not recommended for non-medical personnel to attempt to use UV light to inactivate viruses for the purpose of disinfection of face masks. Cloth masks should be washed frequently in hot soapy water and dried in a drier, Keitel said.

As for the effect of UV on the virus, Neuman said that it crosslinks nucleotides in the virus RNA -- it can damage protein as well, but that is the mechanism of inactivation.

Keitel said that UV light has multiple potential ways of inactivating viruses, including effects on the proteins and on the genetic material.

AFP Fact Check has addressed the topic of using UV light against the novel coronavirus here.

Claim: The virus CANNOT go through healthy skin.

This is true but the reasoning is off, according to Neuman. There aren't any cells with the viral receptor in skin, healthy or unhealthy, so it would not be able to infect.

Keitel said that at this time there is no evidence that this coronavirus can go through healthy skin, and that injury to the skin is required in order for many viruses to gain entry through the skin.

Claim: Vinegar is NOT useful because it does not break down the protective layer of fat.

It is accurate that vinegar is not recommended, but that this is because there is no data to support the claim that it works, and it can be harmful to surfaces, Keitel said.

Claim: NO SPIRITS, NOR VODKA, work. The strongest vodka is 40% alcohol, and you need 65%. Edit: there are a few alcohols more than 65%, and Vodka does come in 50%, but still not strong enough to kill the virus.

This is generally correct, but there is at least one vodka that is 96% ethanol, and would be OK, according to Neuman.

The use of spirits for disinfection is not recommended and has not been studied. Consumption of alcohol for this purpose is discouraged, Keitel said.

Claim: LISTERINE WORKS! It is 65% alcohol.

This is false: Listerine is only 27% ethanol, and would not work reliably, Neuman said.

First, it has not been tested against the coronavirus. Second, not all Listerine contains alcohol. Third, the alcohol content does not exceed about 20%, significantly lower than the recommended concentration for disinfection purposes, said Keitel.

And Listerine does not contact all surfaces where the virus may be located (e.g., nasal, lower respiratory tract), she said.

Claim: The more confined the space, the more concentration of the virus there can be. The more open or naturally ventilated, the less.

This is true, but distance between individuals is much more important. The virus spreads mostly by small droplets (about 10 microns diameter) generated from coughs and sneezes and they do not stay in the air very long and mostly settle out of the air after traveling less than 6 feet, said Leibowitz.

Neuman said: The size of the space doesn't matter so much -- it is a case of whether the virus is in it. Most buildings would have HEPA-filtered air, which is designed to catch coronavirus-sized particles and remove them from what we breathe.

Claim: You have to wash your hands before and after touching mucosa, food, locks, knobs, switches, remote control, cell phone, watches, computers, desks, TV, etc. And when using the bathroom.

This is a harmless and a reasonable idea, Neuman said, while Keitel said that it is recommended to do so after touching potentially contaminated surfaces.

Claim: You have to Moisturize dry hands from so much washing them, because the molecules can hide in the micro cracks. The thicker the moisturizer, the better.

According to Neuman, you most certainly do not have to moisturize, but if you find it more comfortable, you can. It has no bearing on the virus, and is certainly not protective in the way mentioned here.

And Leibowitz said that you may want to moisturize your hands from lots of hand washing but the virus doesnt hide in the cracks.

Claim: Also keep your NAILS SHORT so that the virus does not hide there.

This is not a game of peek-a-boo -- you are unlikely to get respiratory droplets under your fingernails, and even if you did, the virus is unlikely to go from under your fingernails onto your mucosal membranes, Neuman said.

Leibowitz agreed, saying: This virus is spread by the respiratory route and nail length has nothing to do with this.

AFP Fact Check has debunked more than 350 examples of false or misleading information about the novel coronavirus crisis. A complete list of our fact checks on the topic in English can be found here.

See the article here:

Misleading coronavirus information falsely attributed to Johns Hopkins - AFP Factcheck

New study could lead to therapeutic interventions to treat cocaine addiction – Newswise

Newswise Irvine, CA April 22, 2020 A new study explains how cocaine modifies functions in the brain revealing a potential target for therapies aimed at treating cocaine addiction. The study was published this week in Cell Reports.

Researchers from the University of California, Irvine have demonstrated that a key receptor for dopamine, called D2 (D2R), intervenes in the mechanism through which cocaine modifies functions in the striatum, a region of the brain responsible for the psychomotor and rewarding effects of drugs like cocaine, directly involved in the process of addiction.

In our study, we show that D2R signaling over cholinergic interneurons (ChIs) and acetylcholine (Ach) release exerts a major control in the striatum, which is required for the normal functioning of striatal circuits, said Emiliana Borrelli, PhD, a professor of microbiology and molecular genetics, pharmaceutical sciences, and member of the Center for Epigenetics and Metabolism at the UCI School of Medicine.

Cocaine use drastically elevates dopamine levels in the striatum, and causes the dopamine D2 receptor (D2R) to inhibit striatal acetylcholine signaling, resulting in cocaine-induced changes in behavior and the striatal genomic response, said Borrelli. By genetic ablation of D2R in cholinergic interneurons, we disrupt the dopamine-mediated inhibition of these neurons and reduce the addictive effects of drugs like cocaine.

The study indicates that D2R activation in cholinergic interneurons is indeed central to the control of striatal neuronal circuits and significantly affects the motor and cellular responses to cocaine.

Our study emphasizes the importance of the dopaminergic control on striatal responses to psychostimulants and may pave the way for future therapeutic strategies to treat substance use disorders, said Borrelli.

Cocaine is a psychomotor stimulant that when ingested stimulates the central nervous system increasing motor activity and producing euphoria, excitement, and a feeling of reward. Understanding how psychomotor stimulants modify striatal functions is critical to fighting addiction to this drug.

According to the American Addiction Centers, nearly a million American adults (over age 12) struggled with a cocaine use disorder in 2017. The Foundation for a Drug Free World, states cocaine is one of the most dangerous drugs known to man. Once a person begins taking the drug, it has proven almost impossible to become free of its grip physically and mentally. Physically it stimulates key receptors (at nerve endings that sense changes in the body) within the brain that, in turn, create a sense of well-being to which users quickly develop a tolerance. Only higher dosages and more frequent use can bring about the same effect.

This research was supported by funds from the Institut de la Sant et de la Recherche Medicale (INSERM). First author, PhD student R.G. Lewis, received support from a UCI School of Medicine Deans Fellowship and the Dr. Lorna Carlin Scholar Award.

About the UCI School of Medicine

Each year, the UCI School of Medicine educates more than 400 medical students, and nearly 150 doctoral and masters students. More than 700 residents and fellows are trained at UCI Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

See the article here:

New study could lead to therapeutic interventions to treat cocaine addiction - Newswise

As Cuomo Issues New Executive Order, Weill Cornell Medicine Ramps Up COVID-19 Testing – Cornell University The Cornell Daily Sun

As many people yearn to return to some form of normalcy, states are beginning to consider what the reopening of nonessential businesses should look like. In his daily press briefing Gov. Andrew Cuomo (D-N.Y.) said a crucial first step for reopening is widespread COVID-19 testing which New York State currently lacks.

On that same day, Dr. Augustine M.K. Choi, Weill Cornell Dean, announced a new initiative to begin antibody testing employees of Weill Cornell.

Current testing efforts across the state are focused on detecting those with the SARS-CoV-2 virus, but in order to begin reopening businesses people must be tested for previous exposure to the virus.

The current diagnostic used to test patients suspected of having COVID-19 at WCM is a real time reverse transcription polymerase chain reaction, an effective and relatively fast method to detect genetic material. It can be used to detect the RNA present in the SARS-CoV-2 virus.

PCR is the gold standard because its such a highly sensitive and specific test and can deliver reliable and accurate diagnosis in as fast as 2-5 hours. Compared to other available platforms its much faster and more accurate, said Dr. Melissa Cushing, pathology, in Chois update.

However, as institutions begin to test for people who were exposed to the virus and recovered, another method is required antibody testing. Instead of testing for the genetic material of the virus itself, antibody tests search for the antibodies that the body creates in response to COVID-19. These antibodies are formed between three and 15 days after experiencing symptoms, according to Cushing.

As of April 17, testing was made available for New York Presbyterian staff that tested positive for COVID-19 or had a COVID-19-like illness and returned to work.

WCM plans to make more testing available to its staff, as it works to increase its testing capabilities. Cushing predicted that this public testing is at least several weeks away. Experiencing the brunt of statewide shortages of certain materials, WCM also requires access to reagents and more high output platforms to increase its testing capabilities.

We need to really scale up with the amount of reagents we have with our current tests. Then we are really looking to some of the commercial labs to provide the large, high frequency platforms that we already use in our labs so that the process can be much more automated, Cushing said. That is our goal to be testing as many people that need to be tested in our city.

In order to address the testing insufficiencies on a statewide level, the governor issued an executive order on April 17 that directs all public and private labs capable of conducting virology testing to coordinate with the State Department of Health to prioritize coronavirus testing.

The testing and tracing is the guideposts through this. As we are working our way through the next several months the testing, which is informing us as to who can go back to work helping us isolate people, its about testing, Cuomo said in his daily briefing on April 17. Testing is a totally new challenge. Nobody has done this and what we need to do on testing.

According to Cuomo, the lack of infrastructure to facilitate widespread testing mirrors the earlier lack of coordination between hospitals, which the Surge and Flex initiative addressed the initiative coordinated the distribution of scarce medical supplies between public and private hospitals across the state.

Besides the lack of infrastructure, another impasse to wide scale testing is the availability of the materials specifically chemical reagents necessary to run the tests.

Currently, this order will not affect the labs on Cornells Ithaca campus.

Cornell University is not offering any human testing for COVID-19 on campus at this point. We will always follow all state/federal government regulations as appropriate, John Carberry, a University spokesperson, wrote in a statement to The Sun.

Cornell is affiliated with two of the 301 laboratories and hospitals capable of performing viral testing the Allyn B Ley Clinical Laboratory housed in Cornell Health and the Hospital for Special Surgery Dept of Pathology and Laboratory Medicine in New York City.

Initially, 28 laboratories with clinical laboratory permits from the state health department and experience in molecular-based virology could conduct testing. However, this system is unable to meet the demand for the widespread testing needed to reopen New York State.

We dont have a testing system that can do this volume, or that can be ramped up to do this volume. We dont have a public health testing system, its de minimis if you look at what our government department of health have, Cuomo said.

The state has begun its efforts to perform antibody tests on 3,000 individuals to better understand what percentage of the population is currently immune to the virus. The plan is being supported financially by former New York City mayor Michael Bloomberg, who pledged more than $10 million to create a test and trace program.

Original post:

As Cuomo Issues New Executive Order, Weill Cornell Medicine Ramps Up COVID-19 Testing - Cornell University The Cornell Daily Sun

UW president, biochemistry chair and mathematics professor named to American Academy of Arts and Sciences – UW News

Administrative affairs | For UW employees | Honors and awards | News releases | UW and the community

April 23, 2020

Three University of Washington faculty members, including President Ana Mari Cauce, are among the 2020 fellows of the American Academy of Arts and Sciences, one of the nations oldest and most prestigious honorary societies. Trisha Davis, professor and chair of biochemistry at the UW School of Medicine, and Tatiana Toro, the Craig McKibben and Sarah Merner Professor of Mathematics, are also among the 276 artists, scholars, scientists, and leaders in the public, non-profit and private sectors who were announced as new fellows Thursday.

We congratulate these incoming members of the Academy for excelling in a broad array of fields; we want to celebrate them and learn from them, said Nancy C. Andrews, chair of the Board of Directors of the American Academy. When Academy members come together, bringing their expertise and insights to our work, they help develop new insights and potential solutions for some of the most complex challenges we face.

Cauce who was named to the Educational and Academic Leadership section of the Academys Public Affairs, Business and Administration class became the 33rd president of the UW on Oct. 13, 2015 after serving as interim president for seven months and having previously served as provost and executive vice president.

Throughout her career, Cauce has championed access to higher education, including through the Husky Promise, which provides full tuition to eligible Washington students who otherwise could not attend college. As part of her strong belief in ensuring access to higher education for all, just one month into her role as interim president she engaged students in an honest discussion about race and equity, launching an effort to create a more just and diverse community.

Cauce is a professor of Psychology and American Ethnic Studies, with secondary appointments in the Department of Gender, Women and Sexuality Studies and the College of Education. She maintains an active research program, focusing on adolescent development, with a special emphasis on at-risk youth. She is also a strong advocate for women and underrepresented minorities to pursue careers in science, technology, engineering and mathematics.

Davis was named to the Cellular and Developmental Biology (including Genetics), Microbiology and Immunology Section of the Biological Sciences Class of the Academy. Davis and her colleagues explore the dynamics of the chromosome capture that occurs in preparation for cell division.

Impressive molecular machinery tries to assure that each cell resulting from the split receives a proper set of chromosomes. Mistakes in sorting, separating and distributing the chromosomes could cause serious problems, such as cancer. Davis team looks at how the movement and segregation of chromosomes is orchestrated. This chromosome assembly is trial and error, but cells usually can find and fix mistakes. As chromosomes attach to the separation machinery, checkpoints tune into to the connection and the tension it produces. If this quality assurance detects that a chromosome is incorrectly captured, it is released for another try.

The Davis lab uses many ways of examining this and related controls. These include genetic analysis, proteomics, quantitative microscopy, computational modeling and biochemical assays.

Davis holds the Earl W. Davie/ZymoGenetics Chair in Biochemistry at UW Medicine. She also heads the UWs Yeast Resource Center, funded by the National Institutes of Health to develop technologies for exploring protein structure and function.

Toro was named to the Mathematics, Applied Mathematics and Statistics section of the Academys Mathematical and Physical Sciences class. Her research centers on the premise that objects, which may at first appear irregular or disordered, actually have regular features that are quantifiable. Toros work spans geometric measure theory, harmonic analysis and partial differential equations. Toro studies the mathematical questions that come up in systems where the known data are rough, as well as interfaces that arise in noisy minimization problems.

In addition to her research, Toro has also worked to increase diversity in mathematics. She helped launch Latinx in the Mathematical Sciences, including two conferences through the National Science Foundation highlighting the achievements of Latinx mathematicians.

Toro joined the UW faculty in 1996 and her career includes numerous honors and accolades. Last year, she received the UWs Marsha L. Landolt Distinguished Graduate Mentor Award. In 2017, she was elected as a Fellow of the American Mathematical Society. Toro has also been a Guggenheim Fellow, an Alfred P. Sloan Research Fellow and a Simons Foundation Fellow.

Founded in 1780, the American Academy of Arts and Sciences is one of the countrys oldest learned societies and independent policy research centers, convening leaders from the academic, business and government sectors to respond to the challenges facing the nation and the world.

The new members join the company of Academy members elected before them, including Benjamin Franklin and Alexander Hamilton in the eighteenth century; Ralph Waldo Emerson and Maria Mitchell in the nineteenth; and Robert Frost, Martha Graham, Margaret Mead, Milton Friedman, and Martin Luther King, Jr. in the twentieth.

Learn more about the Academys mission, members, and work on its website amacad.org.

# # #

See the article here:

UW president, biochemistry chair and mathematics professor named to American Academy of Arts and Sciences - UW News

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked…

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to MB-107, Mustangs lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. The U.S. Food and Drug Administration (FDA) previously granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-107 for the treatment of XSCID in August 2019.

EMA grants ATMP classifications to new therapeutics that are based on genes or cells and intended as long-term or permanent therapeutic solutions to acute or chronic human diseases at a genetic, cellular or tissue level. The ATMP program provides specific regulatory guidelines for preclinical development, manufacturing and product quality testing of ATMPs and offers incentives, including fee reductions for regulatory advice, recommendations and evaluation and certification of quality and non-clinical data.

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, We are extremely encouraged that the EMA has granted MB-107 with ATMP classification, an important step in establishing our path to market approval and commercialization in Europe. This classification complements the RMAT designation we received last year from the FDA and brings us closer to realizing our goal of commercializing MB-107 for XSCID patients, as these patients are in desperate need of innovative and potentially curative treatment options.

MB-107 is currently being assessed in two Phase 1/2 clinical trials for XSCID: the first in newly diagnosed infants under the age of two at St. Jude Childrens Research Hospital (St. Jude), UCSF Benioff Childrens Hospital in San Francisco and Seattle Childrens Hospital and the second in patients over the age of two who have received prior hematopoietic stem cell transplantation at the National Institutes of Health. Under a licensing partnership with St. Jude, Mustang intends to develop the lentiviral gene therapy for commercial use as MB-107.

About Mustang BioMustang Bio, Inc. (Mustang) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. Mustang was founded by Fortress Biotech, Inc. (FBIO). For more information, visit http://www.mustangbio.com.

ForwardLooking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Story continues

Read the original here:

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked...

Childhood Psychopathology Linked to Higher Levels of Genetic Vulnerability of Adult Depression – Clinical OMICs News

Emotional, social, and psychiatric problems in children and adolescents have been linked to higher levels of genetic vulnerability for adult depression, according to University of Queensland scientists. They made the finding Genetic Associations Between Childhood Psychopathology and Adult Depression and Associated Traits in 42998 Individuals: A Meta-Analysis, which appears inJAMA Psychiatry, while analyzing the genetic data of more than 42,000 children and adolescents from seven cohorts across five European countries.

Christel Middeldorp, MD, PhD, a child and adolescent psychiatrist at the Child Health Research Centre at the University of Queensland, said that researchers have also found a link with a higher genetic vulnerability for insomnia, neuroticism, and body mass index.

By contrast, study participants with higher genetic scores for educational attainment and emotional wellbeing were found to have reduced childhood problems, she pointed out.

We calculated a persons level of genetic vulnerability by adding up the number of risk genes they had for a specific disorder or trait, and then made adjustments based on the level of importance of each gene. We found the relationship was mostly similar across ages.

Adult mood disorders are often preceded by behavioral and emotional problems in childhood. It is yet unclear what explains the associations between childhood psychopathology and adult traits. To investigate whether genetic risk for adult mood disorders and associated traits is associated with childhood disorders, write the investigators.

This meta-analysis examined data from 7 ongoing longitudinal birth and childhood cohorts from the U.K., the Netherlands, Sweden, Norway, and Finland. Starting points of data collection ranged from July 1985 to April 2002. Participants were repeatedly assessed for childhood psychopathology from ages 6 to 17 years. Data analysis occurred from September 2017 to May 2019.

Individual polygenic scores (PGS) were constructed in children based on genome-wide association studies of adult major depression, bipolar disorder, subjective well-being, neuroticism, insomnia, educational attainment, and body mass index (BMI).

Results from this study suggest the existence of a set of genetic factors influencing a range of traits across the life span with stable associations present throughout childhood. Knowledge of underlying mechanisms may affect treatment and long-term outcomes of individuals with psychopathology.

The results indicate there are shared genetic factors that affect a range of psychiatric and related traits across a persons lifespan. Around 50 percent of children and adolescents with psychiatric problems, such as attention deficit hyper-activity disorder (ADHD), continue to experience mental disorders as adults, and are at risk of disengaging with their school community among other social and emotional problems, added Middeldorp.

Our findings are important as they suggest this continuity between childhood and adult traits is partly explained by genetic risk, she continued. Individuals at risk of being affected should be the focus of attention and targeted treatment. Although genetic vulnerability is not accurate enough at this stage to make individual predictions about how a persons symptoms will develop over time, it may become so in the future, in combination with other risk factors.

Middeldorp believes that this study and others may support precision medicine by providing targeted treatments to children at the highest risk of persistent emotional and social problems.

Read more:

Childhood Psychopathology Linked to Higher Levels of Genetic Vulnerability of Adult Depression - Clinical OMICs News

Gdask scientist makes crucial headway in understanding killer virus by isolating COVID-19 DNA from infected patient – The First News

Dr. ukasz Rbalski (pictured) from Gdask University is the first in Poland to obtain the full genetic sequence of the SARS-CoV-2 coronavirus, isolated directly from a Polish patient. Adam Warawa/PAP

The full DNA sequence of the coronavirus virus has been taken from an infected patient after being isolated by scientists at Gdask University.

By unravelling the genetic sequence, the researchers can learn a variety of crucial information about the disease, such as how the virus deceives the human body, weakening its immune system.

A fragment of the genetic sequence of the coronavirus fully isolated by Dr. Rbalski.Adam Warawa/PAP

Other clues include COVID-19s evolutionary and geographic origins, how it found itself in Poland and how it has changed since the outbreak in China.

Team leader Dr. ukasz Rbalski at the Gdask University and Medical Academys joint Intercollegiate Faculty of Biotechnology said: Genetic material must meet many qualitative and quantitative standards in order to be decoded.

The data obtained will allow scientists from around the world to consider Poland in their research related to the epidemiology of COVID-19 disease.Public domain

In the case of viruses whose genetic material is single-stranded RNA, methods are used to multiply the amount of genetic material.

Normally, this has been done by replicating viral particles in laboratories. Nowadays, thanks to achievements in the field of molecular biology, a shorter pathway can be used without the need for virus culture.

By unravelling the genetic sequence, the researchers can learn a variety of crucial information about the disease, such as how the virus deceives the human body, weakening its immune system.Adam Warawa/PAP

The equipment used to decode coronavirus was previously used during the Ebola epidemic.

Dr. Rbalski used the latest generation of sequencers from Oxford Nanopore Technologies, which have bioinformatic protocols that limit the risk of results distortion.

Dr. Rbalskis research is published in the global GISAID database.Uniwersytet Gdaski

The GISAID database is the biggest resource of DNA sequences worldwide scientists have already uploaded over 5,000 of them and now the collection includes one from a Polish patient.

The University Clinical Centre in Gdasks Hematology Laboratory is currently carrying out further sequencing of viruses from Polish patients.

Dr. Rbalski used the latest generation of sequencers from Oxford Nanopore Technologies, which have bioinformatic protocols that limit the risk of results distortion.Adam Warawa/PAP

The next package of data will be sent to GISAID within the next few days.

The research has been published in the international GISAID database so that it can be widely used for research on vaccines and medicine for the coronavirus.

Visit link:

Gdask scientist makes crucial headway in understanding killer virus by isolating COVID-19 DNA from infected patient - The First News

Ethiopia’s Ministry of Health Holds Webinar With Diaspora on COVID-19 Response at Tadias Magazine – Tadias Magazine

Ethiopia pardons more than 4,000 prisoners to help prevent coronavirus spread

Young and middle-aged people, barely sick with covid-19, are dying from strokes

By The Washington Post

Doctors sound alarm about patients in their 30s and 40s left debilitated or dead. Some didnt even know they were infected. Read more

Global coronavirus death toll surpasses 200,000, as world leaders commit to finding vaccine

By NBC News

The global coronavirus death toll surpassed 200,000 on Saturday, according to John Hopkins University data. The grim total was reached a day after presidents and prime ministers agreed to work together to develop new vaccines, tests and treatments at a virtual meeting with both the World Health Organization (WHO) and Bill & Melinda Gates Foundation. We will only halt COVID-19 through solidarity, said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. Countries, health partners, manufacturers, and the private sector must act together and ensure that the fruits of science and research can benefit everybody. As the U.S. coronavirus death tollpassed 51,000 people, according to an NBC News tally, President Donald Trump took no questions at his White House briefing on Friday, after widespread mockery for floating the idea that light, heat and disinfectants could be used to treat coronavirus patients.

Read more

Germany to start first coronavirus vaccine trial

By DW

German Health Minister Jens Spahn has announced the first clinical trials of a coronavirus vaccine. The Paul Ehrlich Institute (PEI), the regulatory authority which helps develop and authorizes vaccines in Germany, has given the go-ahead for the first clinical trial of BNT162b1, a vaccine against the SARS-CoV-2 virus. It was developed by cancer researcher and immunologist Ugur Sahin and his team at pharmaceutical company BioNTech, and is based on their prior research into cancer immunology. Sahin previously taught at the University of Mainz before becoming the CEO of BioNTech. In a joint conference call on Wednesday with researchers from the Paul Ehrlich Institute, Sahin said BNT162b1 constitutes a so-called RNA vaccine. He explained that innocuous genetic information of the SARS-CoV-2 virus is transferred into human cells with the help of lipid nanoparticles, a non-viral gene delivery system. The cells then transform this genetic information into a protein, which should stimulate the bodys immune reaction to the novel coronavrius.

Read more

Webinar on COVID-19 and Mental Health: Interview with Dr. Seble Frehywot

By Liben Eabisa | TADIAS

Dr. Seble Frehywot, an Associate Professor of Global Health & Health Policy at George Washington University in Washington, D.C. and her colleague Dr. Yianna Vovides from Georgetown University will host an online forum next week on April 30th focusing on the COVID-19 pandemic and its impact on mental health. Dr. Seble who is also the Director of Global Health Equity On-Line Learning at George Washington University told Tadias that the virtual conference titled Peoples Webinar: Addressing COVID-19 By Addressing Mental Health is open to the public and available for viewing worldwide. Read more

CDC director warns second wave of coronavirus is likely to be even more devastating

By The Washington Post

Even as states move ahead with plans to reopen their economies, the director of the Centers for Disease Control and Prevention warned Tuesday that a second wave of the novel coronavirus will be far more dire because it is likely to coincide with the start of flu season. Theres a possibility that the assault of the virus on our nation next winter will actually be even more difficult than the one we just went through, CDC Director Robert Redfield said in an interview with The Washington Post. And when Ive said this to others, they kind of put their head back, they dont understand what I meanWere going to have the flu epidemic and the coronavirus epidemic at the same time, he said. Having two simultaneous respiratory outbreaks would put unimaginable strain on the health-care system, he said. The first wave of covid-19, the disease caused by the coronavirus, has already killed more than 42,000 people across the country. It has overwhelmed hospitals and revealed gaping shortages in test kits, ventilators and protective equipment for health-care workers.

Read more

Americans at World Health Organization transmitted real-time information about coronavirus to Trump administration

By The Washington Post

More than a dozen U.S. researchers, physicians and public health experts, many of them from the Centers for Disease Control and Prevention, were working full time at the Geneva headquarters of the World Health Organization as the novel coronavirus emerged late last year and transmitted real-time information about its discovery and spread in China to the Trump administration, according to U.S. and international officials. A number of CDC staff members are regularly detailed to work at the WHO in Geneva as part of a rotation that has operated for years. Senior Trump-appointed health officials also consulted regularly at the highest levels with the WHO as the crisis unfolded, the officials said. The presence of so many U.S. officials undercuts President Trumps assertion that the WHOs failure to communicate the extent of the threat, born of a desire to protect China, is largely responsible for the rapid spread of the virus in the United States. Read more

In Ethiopia, Dire Dawa Emerges as Newest Coronavirus Hot Spot

By Africa News

The case count as of April 20 had reached 111 according to health minister Lia Tadesses update for today. Ethiopia crossed the 100 mark over the weekend. All three cases recorded over the last 24-hours were recorded in the chartered city of Dire Dawa with patients between the ages of 11 18. Two of them had travel history from Djibouti. Till date, Ethiopia has 90 patients in treatment centers. The death toll is still at three with 16 recoveries. A patient is in intensive care. Read more

COVID-19: Interview with Dr. Tsion Firew, an Ethiopian Doctor on the Frontline in NYC

Dr. Tsion Firew is Doctor of Emergency Medicine and Assistant Professor at Columbia University. She is also Special Advisor to the Ministry of Health in Ethiopia. (Courtesy photo)

By Liben Eabisa

In New York City, which has now become the global epicenter of the coronavirus pandemic, working as a medical professional means literally going to a war zone, says physician Tsion Firew, a Doctor of Emergency Medicine and Assistant Professor at Columbia University, who has just recovered from COVID-19 and returned to work a few days ago. Indeed the statistics coming out of New York are simply shocking with the state recording a sharp increase in death toll this months surpassing 10,000 and growing. According to The New York Times: The numbers brought into clearer focus the staggering toll the virus has already taken on the largest city in the United States, where deserted streets are haunted by the near-constant howl of ambulance sirens. Far more people have died in New York City, on a per-capita basis, than in Italy the hardest-hit country in Europe. At the heart of the solution both in the U.S. and around the world is more testing and adhering to social distancing rules until such time as a proper treatment and vaccine is discovered, says Dr. Tsion, who is also a Special Advisor to the Ministry of Health in Ethiopia. Dr. Tsion adds that at this moment we all as humanity have one enemy: the virus. And whats going to win the fight is solidarity. Listen to the interview

Ethiopia Opens Aid Transport Hub to Fight Covid-19

By AFP

Ethiopia and the United Nations on Tuesday opened a humanitarian transport hub at Addis Ababa airport to move supplies and aid workers across Africa to fight coronavirus. The arrangement, which relies on cargo services provided by Ethiopian Airlines, could also partially offset heavy losses Africas largest carrier is sustaining because of the pandemic. An initial shipment of 3 000 cubic metres of supplies most of it personal protective equipment for health workers will be distributed within the next week, said Steven Were Omamo, Ethiopia country director for the World Food Programme (WFP). This is a really important platform in the response to Covid-19, because what it does is it allows us to move with speed and efficiency to respond to the needs as they are unfolding, Omamo said, referring to the disease caused by the coronavirus. The Addis gateway is one of eight global humanitarian hubs set up to facilitate movement of aid to fight Covid-19, according to WFP.

Read more

Covid-19: Ethiopia to buy life insurance for health workers

By TESFA-ALEM TEKLE | AFP

The Ethiopian government is due to buy life insurance for health professionals in direct contact with Covid-19 patients. Health minister Lia Tadesse said on Tuesday that the government last week reached an agreement with the Ethiopian Insurance Corporation but did not disclose the value of the cover. The two sides are expected to sign an agreement this week to effect the insurance grant. According to the ministry, the life insurance grant is aimed at encouraging health experts who are the most vulnerable to the deadly coronavirus. Members of the Rapid Response Team will also benefit.

Read more

U.N. says Saudi deportations of Ethiopian migrants risks spreading coronavirus

By Reuters

The United Nations said on Monday that deportations of illegal migrant workers by Saudi Arabia to Ethiopia risked spreading the coronavirus and it urged Riyadh to suspend the practice for the time being.

Read more

Ethiopias capital launches door-to-door Covid-19 screening

Getty Images

By TESFA-ALEM TEKLE | AFP

Ethiopias capital, Addis Ababa is due to begin a door-to-door mass Covid-19 screening across the city, Addis Ababa city administration has announced. City deputy Mayor, Takele Uma, on Saturday told local journalists that the mass screening and testing programme will be started Monday (April 13) first in districts which are identified as potentially most vulnerable to the spread of the highly infectious coronavirus. The aggressive city-wide screening measure intends to identify Covid-19 infected patients and thereby to arrest a potential virus spread within communities. He said, the mass screening will eventually be carried out in all 117 districts, locally known as woredas, of the city, which is home to an estimated 7 million inhabitants. According to the Mayor, the door-to-door mass Covid-19 screening will be conducted by more than 1,200 retired health professionals, who responded to governments call on the retired to join the national fight against the coronavirus pandemic.

Read more

Worldwide deaths from the coronavirus hit 100,000

By The Associated Press

The worldwide death toll from the coronavirus has hit 100,000, according to the running tally kept by Johns Hopkins University. The sad milestone comes as Christians around the globe mark a Good Friday unlike any other in front of computer screens instead of in church pews. Meanwhile, some countries are tiptoeing toward reopening segments of their battered economies. Public health officials are warning people against violating the social distancing rules over Easter and allowing the virus to flare up again. Authorities are using roadblocks and other means to discourage travel.

Read more

Ethiopia COVID-19 Response Team: Interview with Mike Endale

By Liben Eabisa | TADIAS

A network of technology professionals from the Ethiopian Diaspora known as the Ethiopia COVID-19 Response Team has been assisting the Ethiopian Ministry of Health since the nations first Coronavirus case was confirmed on March 13th. The COVID-19 Response Team has since grown into an army of more than a thousand volunteers. Mike Endale, a software developer based in Washington, D.C., is the main person behind the launch of this project. Read more

Ethiopia eyes replicating Chinas successes in applying traditional medicine to contain COVID-19

By CGTN Africa

The Ethiopian government on Thursday expressed its keen interest to replicate Chinas positive experience in terms of effectively applying traditional Chinese medicine to successfully contain the spread of COVID-19 pandemic in the East African country.

This came after high-level officials from the Ethiopian Ministry of Innovation and Technology (MoIT) as well as the Ethiopian Ministry of Health (MoH) held a video conference with Traditional Chinese Medicine (TCM) practitioners and researchers on ways of applying the TCM therapy towards controlling the spread of coronavirus pandemic in the country, the MoIT disclosed in a statement issued on Thursday.

China, in particular, has agreed to provide to Ethiopia the two types of Chinese traditional medicines that the country applied to successfully treat the first two stages of the novel coronavirus, a statement from the Ethiopian Ministry of Innovation and Technology read.

Read more

WHO Director Slams Racist Comments About COVID-19 Vaccine Testing

The Director General of the World Health Organization, Dr. Tedros Adhanom Ghebreyesus, has angrily condemned recent comments made by scientists suggesting that a vaccine for COVID-19 should be tested in Africa as racist and a hangover from the colonial mentality. (Photo: WHO)

By BBC

The head of the World Health Organization (WHO) has condemned as racist the comments by two French doctors who suggested a vaccine for the coronavirus could be tested in Africa.

Africa cant and wont be a testing ground for any vaccine, said Director General Dr Tedros Adhanom Ghebreyesus.

The doctors remarks during a TV debate sparked outrage, and they were accused of treating Africans like human guinea pigs.

One of them later issued an apology.

When asked about the doctors suggestion during the WHOs coronavirus briefing, Dr Tedros became visibly angry, calling it a hangover from the colonial mentality.

It was a disgrace, appalling, to hear during the 21st Century, to hear from scientists, that kind of remark. We condemn this in the strongest terms possible, and we assure you that this will not happen, he said.

Read more

Ethiopia declares state of emergency to curb spread of COVID-19

By Reuters

Ethiopias prime minister, Abiy Ahmed, on Wednesday declared a state of emergency in the country to help curb the spread of the new coronavirus, his office said on Twitter. Considering the gravity of the #COVID19, the government of Ethiopia has enacted a State of Emergency, Abiys office said.

Ethiopia virus cases hit 52, 9-month-old baby infected

By TESFA-ALEM TEKLE | AFP

Ethiopia on Tuesday reported eight new Covid-19 cases, the highest number recorded so far in one day since the country confirmed its first virus case on March 12. Among the new patients that tested positive for the virus were a 9-month-old infant and his mother who had travelled to Dubai recently. During the past 24 hours, we have done laboratory tests for a total of 264 people and eight out of them have been diagnosed with coronavirus, raising the total confirmed number of Covid-19 patients in Ethiopia to 52, said Health Minister Dr Lia Tadese. According to the Minister, seven of the newly confirmed patients had travel histories to various countries. They have been under forced-quarantine in different designated hotels in the capital, Addis Ababa. Five of the new patients including the 9-month-old baby and the mother came from Dubai while the two others came from Thailand and the United Kingdom, she said

Read more

The coronavirus is infecting and killing black Americans at an alarmingly high rate

By The Washington Post

As the novel coronavirus sweeps across the United States, it appears to be infecting and killing black Americans at a disproportionately high rate, according to a Washington Post analysis of early data from jurisdictions across the country. The emerging stark racial disparity led the surgeon general Tuesday to acknowledge in personal terms the increased risk for African Americans amid growing demands that public-health officials release more data on the race of those who are sick, hospitalized and dying of a contagion that has killed more than 12,000 people in the United States. A Post analysis of what data is available and census demographics shows that counties that are majority-black have three times the rate of infections and almost six times the rate of deaths as counties where white residents are in the majority.

Read more

In China, Wuhans lockdown officially ends after 11 weeks

After 11 weeks or 76 days Wuhans lockdown is officially over. On Wednesday, Chinese authorities allowed residents to travel in and out of the besieged city where the coronavirus outbreak was first reported in December. Many remnants of the months-long lockdown, however, remain. Wuhans 11 million residents will be able to leave only after receiving official authorization that they are healthy and havent recently been in contact with a coronavirus patient. To do so, the Chinese government is making use of its mandatory smartphone application that, along with other government surveillance, tracks the movement and health status of every person.

Read more

U.S. hospitals facing severe shortages of equipment and staff, watchdog says

By The Washington Post

As the official U.S. death toll approached 10,000, U.S. Surgeon General Jerome M. Adams warned that this will be the hardest and saddest week of most Americans lives.

Read more

Ethio-American Tech Company PhantomALERT Offers Free App to Track & Map COVID-19 Outbreak

By Tadias Staff

PhantomALERT, a Washington D.C.-based technology company announced, that its offering a free application service to track, report and map COVID-19 outbreak hotspots in real time. In a recent letter to the DC government as well as the Ethiopian Embassy in the U.S. the Ethiopian-American owned business, which was launched in 2007, explained that over the past few days, they have redesigned their application to be a dedicated coronavirus mapping, reporting and tracking application. The letter to the Ethiopian Embassy, shared with Tadias, noted that PhantomALERTs technology will enable the Ethiopian government (and all other countries across the world) to locate symptomatic patients, provide medical assistance and alert communities of hotspots for the purpose of slowing down the spread of the Coronavirus.

Read more

2nd COVID-19 death confirmed in Ethiopia

By Dr. Lia Tadesse (Minister, Ministry of Health, Ethiopia)

It is with great sadness that I announce the second death of a patient from #COVID19 in Ethiopia. The patient was admitted on April 2nd and was under strict medical follow up in the Intensive Care Unit. My sincere condolences to the family and loved ones.

Read more

The Next Coronavirus Test Will Tell You If You Are Now Immune. And Its Fast.

People line up in their cars at the COVID-19 testing area at Roseland Community Hospital on April 3, 2020, in Chicago. (E. Jason Wambsgans / Chicago Tribune)

By Chicago Tribune

A new, different type of coronavirus test is coming that will help significantly in the fight to quell the COVID-19 pandemic, doctors and scientists say. The first so-called serology test, which detects antibodies to the virus rather than the virus itself, was given emergency approval Thursday by the U.S. Food and Drug Administration. And several more are nearly ready, said Dr. Elizabeth McNally, director of the Northwestern University Feinberg School of Medicine Center for Genetic Medicine.

Read more

Read more from the original source:

Ethiopia's Ministry of Health Holds Webinar With Diaspora on COVID-19 Response at Tadias Magazine - Tadias Magazine

Immunity and our DNA: Why women are the stronger sex – The Age

The Better Half: On the Genetic Superiority of Women is by Dr Sharon Moalem (male); a neuroscientist and evolutionary biologist. Its a fascinating, unexpected and thought-provoking argument that the simple fact of having two X chromosomes, instead of one X chromosome and one Y chromosome, is the secret to womens underappreciated success in the game of life.

Dr Sharon Moalem is a science author.

A quick refresher on chromosomes: among the 23 pairs of chromosomes X-shaped twists of DNA that are the encyclopaedia of us found in every human cell, are two sex chromosomes. In genetic females, these two sex chromosomes are both an X chromosome. In genetic males, one is an X chromosome and one is a Y chromosome.

We inherit one sex chromosome from our father and one from our mother; genetic females inherit one X sex chromosome from each parent, and genetic males inherit an X sex chromosome from the mother, and a Y sex chromosome from their father.

The X chromosome is the genetic powerhouse of the sex chromosomes, containing more than 1000 genes that orchestrate a huge number of vital cellular processes. In contrast, the Y chromosome is a stunted thing that only carries about 70 genes, most of which are involved in the production of sperm.

In genetic females, only one of their two X chromosomes is needed, so the second X chromosome is deactivated or silenced when that person is merely a bundle of cells in the uterus. The silenced X chromosome gets condensed down into a bit of cellular debris called a Barr body.

For a long time, that second, silenced X chromosome was assumed to be dead. But it turns out that second X chromosome in the cells of genetic females is actually a genetic back-up plan, helping the cell and the person to survive by throwing a genetic lifeline when things get tough. Far from being inert, about 23 per cent of those thousand or so genes on the silenced X chromosome are still active.

Dr Sharon Moalem on women having an extra X chromosome: Its like having two toolboxes. One toolbox may have a broken hammer, so you use the hammer from the second box."Credit:Getty Images

Moalem argues that this back-up set of genes gives women a significant survival advantage, as evidenced by the fact that women consistently outlive men, even in times of hardship.

Having the use of two X chromosomes makes females more genetically diverse, and the ability to rely on that diverse genetic knowledge is why females always come out on top, he writes.

This advantage is particularly evident with the immune system. Moalem recalls his time tending to HIV-positive children at an orphanage in Bangkok, and his observation that the HIV-positive boys were consistently more likely to get sick with opportunistic infections than the HIV-positive girls.

Credit:

He goes on to note that HIV-positive men are also more likely than HIV-positive women to develop tuberculosis and pneumonia, while HIV-positive women tend to have higher immune-cell counts a sign of immunological strength in the early stages of HIV infection than men do.

The X chromosome carries a large number of genes involved in immune system functioning. Moalem argues that because women have two copies of the X chromosome, they are able to produce a more diverse and effective population of immune cells than if they relied on the immune genes of only one X chromosome, as men do.

But there is a price for that more aggressive immune response; sometimes it goes overboard and starts overreacting to benign things, such as our own cells. This is the phenomenon of autoimmunity, and it disproportionally affects women.

If a microbe is the wolf, and its dressing up like Grandma, better trying to kill Grandma every once in a while than to risk being fooled by a wolf dressed like Grandma, he explains.

Having two X chromosomes also offers an unparalleled advantage if it happens that a gene on one of those chromosomes is dangerously mutated.

Loading

Say you inherit a malfunctioning gene on the X chromosome from your mother that might be associated with developmental problems. If you also have inherited an X chromosome from your father that carries a functional copy of that gene, you have a back-up, an understudy, for that faulty gene. But if you inherit a Y chromosome from your father, youre stuck with the faulty one.

This is why so-called X-linked intellectual disabilities almost entirely affect genetic males; more than 100 genes associated with intellectual disabilities have been found on the X chromosome.

Moalem also highlights a problem that numerous female authors before him have also drawn attention to: that medical science and medicine still view women as being biologically the same as men. That persistent ignorance one might even call it wilful denialism has had some devastating consequences.

Women with autoimmune conditions have long had their symptoms dismissed or trivialised by the medical establishment, which was working on the assumption that these diseases were equally prevalent in men and women.

Not that that lack of understanding has slowed females down too much. As Moalem points out, theres only one way to judge the winner in the genetic battle of the sexes: The real test of ones mettle is being able to survive the challenges of life, he writes. So, who is left standing at the end of life?

Thats right. Women.

Bianca Nogrady is the editor of The Best Australian Science Writing 2019 (NewSouth).

Visit link:

Immunity and our DNA: Why women are the stronger sex - The Age

Nobel laureate Luc Montagnier inaccurately claims that the novel coronavirus is man-made and contains genetic material from HIV – Health Feedback

CLAIM

"this coronavirus genome contained sequences of another virus [] the HIV virus (AIDS virus)"

DETAILS

Inaccurate: Genomic analyses indicate that the virus has a natural origin, and was not engineered. The so-called unique protein sequence insertions found in the 2019 novel coronavirus can be found in many other organisms, not just HIV.

KEY TAKE AWAY

Genomic analyses of the novel coronavirus show that it was not engineered. In addition, the claim that its genome contains inserted HIV sequences is based on a now-withdrawn preprint of a study that contained significant flaws in design and execution. The so-called HIV insertions identified by the authors are in fact gene sequences that can also be found in many other organisms besides HIV.

REVIEW Numerous articles published in April 2020 report that Nobel laureate Luc Montagnier claimed that SARS-CoV-2 is a manipulated virus that was accidentally released from a laboratory in Wuhan, China and that Indian researchers have already tried to publish the results of the analyses that showed that this coronavirus genome contained sequences of another virus [] the HIV virus (AIDS virus). The claim that SARS-CoV-2 contains HIV insertions began circulating in January 2020, and was propagated by outlets such as Zero Hedge and Infowars. Health Feedback covered this claim in early February 2020, and found it to be inaccurate.

Firstly, genomic analysis of the novel coronavirus, published in Nature Medicine, has demonstrated that the virus is not the product of bioengineering, but is rather of natural origin[1]. The current most likely theory, based on what scientists know about viral evolution, is that the virus first emerged in pangolins or bats (or both) and later developed the ability to infect humans. This ability to infect human cells is conferred by the so-called spike (S) protein, which is located on the surface of the enveloping membrane of SARS-CoV-2.

After the 2003-2005 SARS outbreak, researchers identified a set of key amino acids within the S protein which give SARS-CoV-1 a super-affinity for the ACE2 target receptor located on the surface of human cells[2,3]. Surprisingly, the S protein of the current SARS-CoV-2 does not contain this optimal set of amino acids[1], yet is nonetheless able to bind ACE2 with a greater affinity than SARS-CoV-1[4]. This finding suggests that SARS-CoV-2 evolved independently and undermines the claim that it was manmade[1]. Indeed, the best engineering strategy would have been to harness the known and efficient amino acid sequences already described in SARS-CoV-1 order to produce a more optimal molecular design for SARS-CoV-2. The authors of the Nature Medicine study[1] concluded that Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.

Secondly, the claim that SARS-CoV-2 contains HIV insertions is based on a preprint of a research study uploaded to bioRxiv on 2 February 2020. A preprint is a study in progress that has not been peer-reviewed by other scientists. The authors of the preprint, titled Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag, claimed to have found 4 insertions in the spike glycoprotein (S) which are unique to 2019-nCoV and are not present in other coronaviruses. The authors further asserted that all of [these inserts] have identity/similarity to amino acids residues in key structural proteins of HIV-1 [which] is unlikely to be fortuitous in nature.

The work was swiftly criticized by experts. In this Forbes article, Arinjay Banerjee, a postdoctoral fellow at McMaster University who has studied coronaviruses, said that:

The authors compared very short regions of proteins in the novel coronavirus and concluded that the small segments of proteins were similar to segments in HIV proteins. Comparing very short segments can often generate false positives and it is difficult to make these conclusions using small protein segments.

Researchers also took to Twitter to demonstrate this problem first-hand. Trevor Bedford, a faculty member at the Fred Hutchinson Cancer Research Center who studies viral evolution, re-analyzed the gene and protein sequences used by the authors and found that the so-called unique inserts appeared in many other organisms, including Cryptosporidium and Plasmodium malariae, which cause cryptosporidiosis and malaria, respectively.

Assistant professor at Stanford University Silvana Konermann also checked the authors findings and came to the same conclusion, calling the similarity spurious.

This has also been independently confirmed in another published analysis[5]. In other words, these sequences are not insertions, but are rather common sequences found in numerous other organisms such as bacteria and parasites. Therefore, the existence of these sequences in SARS-CoV-2 does not provide evidence of a link to HIV, nor that scientists purposely inserted HIV sequences into the SARS-CoV-2 genome.

In summary, genomic analysis of the virus indicates that it does not contain so-called HIV insertions and that it was not engineered in a lab. Evidence points to the virus having a natural origin.

The only thing accurate about these articles is that Nobel Prize winner and virologist Luc Montagnier did in fact make these claims. Although he holds impressive scientific credentials, his claims run contrary to credible scientific evidence. And despite having won the Nobel Prize in Physiology or Medicine in 2008 for his co-discovery of the link between HIV and AIDS, Montagnier now promotes widely discredited theories such as the pseudoscience of homeopathy and that autism is caused by bacteria that emit electromagnetic waves. Articles which repeat Montagniers claims without critically evaluating their veracity exhibit the common appeal to authority fallacy, in which something is assumed to be true simply because the person saying it is considered to be an expert, thereby misleading readers into believing that this theory is scientifically credible. This demonstrates the importance of verifying scientific claims with other experts in the same field, rather than simply taking such claims from a single expert at face value.

SCIENTISTS FEEDBACK [These comments come from an evaluation of a related claim.] Aaron T. Irving, Senior Research Fellow, Duke-NUS Medical School:Its easier to believe misinformation when it is mixed with truth. The region highlighted in the pre-print is indeed an insertion in nCoV-2019 relative to its bat ancestors and indeed it has high identity to the HIV gp120/gag. However, the authors chose to align only this small region and not do a basic check on whether there were other sequences which were also homologous (showing high degree of similarity/identity). As it turned out, the region is also homologous to many unrelated sequences. As such, the conclusions drawn from the data are no longer valid and there are many open-ended questions regarding this region highlighted. I see the authors themselves agree with this criticism by other scientists and have voluntarily withdrawn their preprint pending a much deeper investigation.

The author of this article by European Scientist also compared the genome sequences of SARS-CoV-2 and HIV using the Basic Local Alignment Search Tool (BLAST), developed by the U.S. National Institutes of Health, and found no significant similarity, explaining that In plain English, SARS-CoV-2 is not made of the bat coronavirus and small bits of the HIV virus. Readers who wish to verify the level of sequence identity between the two viruses for themselves are welcome to follow the steps listed in the article.

Read more:

Nobel laureate Luc Montagnier inaccurately claims that the novel coronavirus is man-made and contains genetic material from HIV - Health Feedback

Concert Genetics Presents Real-World Data on Utilization of NGS-Based Diagnostic Tests in NCCN 2020 Abstract – news-herald.net

NASHVILLE, Tenn., April 1, 2020 /PRNewswire/ --Concert Genetics, a technology company dedicated to advancing precision medicine, today announced the publication ofreal-world data on utilization and coding variability in medical claims for Next-Generation Sequencing (NGS)-based diagnostic tests. The study was done in collaboration with Merck, known as MSD outside the United States and Canada, and focuses on diagnostic testing among cancer patients in the U.S. It was accepted for presentation in the General Poster Session at the National Comprehensive Cancer Network's NCCN 2020 Annual Conference and is available online from JNCCNJournal of the National Comprehensive Cancer Network.

"The breathtaking speed of innovation in precision medicine is outpacing the healthcare system's ability to adapt," said Rob Metcalf, CEO of Concert Genetics. "As a result, the real-world data for observational research is often unavailable, too sparse, or insufficiently granular for evidence development. Concert's focus is delivering transparency and connectivity in genetic testing to enable precision medicine, and we were delighted to utilize our proprietary data and patented analytics to make this research possible."

The joint abstract is titled "Real-World Utilization and Coding Variability in Medical Claims for Next-Generation Sequencing (NGS)-Based Diagnostic Tests Among Cancer Patients in the U.S." It was scheduled to be presented at NCCN 2020, which was postponed due to COVID-19. The abstract is available at the following URL: https://jnccn.org/view/journals/jnccn/18/3.5/article-pHSR20-083.xml.

Concert's proprietary method for collecting and analyzing data in this space is described in U.S. Patent No. 10,223,501: "Tracking, Monitoring, and Standardizing Molecular and Diagnostic Testing Products and Services."

About Concert GeneticsConcert Genetics is a software and managed services company that advances precision medicine by providing thedigital infrastructure for reliable and efficient management of genetic testing. Concert's market-leading genetic test order management platform leverages a proprietary database of the U.S. clinical genetic testing market (today more than 140,000 testing products) and integrates with leading electronic health record and laboratory information management systems. Concert also provides genetic testing management solutions to leading health plans across the U.S. Learn more at http://www.ConcertGenetics.com.

CONTACT

Nick TazikConcert Genetics(615) 861-2634ntazik@concertgenetics.com

Originally posted here:

Concert Genetics Presents Real-World Data on Utilization of NGS-Based Diagnostic Tests in NCCN 2020 Abstract - news-herald.net

What scientists know about COVID-19 — and what they don’t – PBS NewsHour

Siddhartha Mukherjee:

Well, there are several things we have learned.

First of all, we have learned that a that the virus is mainly transmitted through respiratory droplets or so-called fomites. That's the main mode of transmission.

The second thing that we have learned, or trying to learn, we're in the middle of learning, is that there are several people who are asymptomatic who may be shedding virus. That's a very, very important idea. That is to say that there may be a child or someone who doesn't have any symptoms, no fever, no diarrhea, no respiratory symptoms, but nonetheless is shedding the virus.

We need to identify those people and isolate and potentially quarantine them, so that they don't keep spreading the virus.

The third thing that we are learning, which we haven't learned for sure, is that there seems to be if you do the right kind of test, there seems to be a way to predict whether you're going to have very severe disease vs. a more mild form of the disease.

And that helps because that will help us triage patient to those who are either going to be sick and therefore require urgent attention vs. those who may become less sick and may be able to be managed more conservatively too.

Continued here:

What scientists know about COVID-19 -- and what they don't - PBS NewsHour

UVA Finds Way to Improve Cancer Outcomes by Examining Patients’ Genes – University of Virginia

By mining a vast trove of genetic data,researchers at theUniversity of Virginia School of Medicineare enhancing doctors ability to treat cancer, predict patient outcomes and determine which treatments will work best for individual patients.

The researchers have identified inherited variations in our genes that affect how well a patient will do after diagnosis and during treatment. With that information in hand, doctors will be able to examine a patients genetic makeup to provide truly personalized medicine.

Oncologists can estimate how a patient will do based on the grade of the tumor, the stage, the age of the patient, the type of tumor, etc. We found [adding a single genetic predictor] can improve our predictive ability by 5% to 10%, said UVAs Anindya Dutta. Many of the cancers had multiple inherited genetic change that were predictive of outcome, so if we add those in, instead of a 10% increase we might get a 30% increase in our ability to predict accurately how patients will do with our current therapy. Thats amazing.

Dutta, the chair of UVAs Department of Biochemistry and Molecular Genetics, believes reviewing the inherited genetic makeup of a patient can provide similar benefits for predicting outcome and choosing therapy for many, many other conditions, from diabetes to cardiac problems. As such, the approach represents a major step forward in doctors efforts to tailor treatments specifically to the individuals needs and genetic makeup.

The research offers answers to questions that have long perplexed doctors.Every clinician has this experience: Two patients come in with exactly the same cancersame grade, same stage, received the same treatment. One of them does very well, and the other one doesnt, Dutta said.The assumption has always been that there is something about the two that we didnt understand, like maybe there are some tumor-specific mutations that one patient had but the other did not. But it occurred to us that with all this genomic data, there is another hypothesis that we could test.

Instead of a 10% increase we might get a 30% increase in our ability to predict accurately how patients will do with our current therapy. Thats amazing.

- Anindya Dutta

To determine if genetic differences in the patients could be the answer, Dutta and his colleagues did a deep dive into the Cancer Genome Atlas, an enormous repository of genetic information assembled by the National Institutes of Healths National Cancer Institute. The researchers sought to correlate inherited genetic variations with patient outcomes.

This incredibly smart M.D.-Ph.D. student in the lab, Mr.Ajay Chatrath,decided that this was a perfect time to explore this, Dutta recalled. With the help of cloud computing services at UVA, we managed to download all this genomic sequencing data and identify what are known as germline variants not just tumor-specific mutations, but the mutations that were inherited from the parents and are present in all cells of the patient.

The researchers started small, but soon realized how quickly the work could be done and how big the benefits could be. Once we realized this was a very easy thing to do, we went on to do all 33 cancers and all 10,000 patients, and that took another six months, Dutta said. All of this came together beautifully. It was very exciting that every single member in the lab contributed to the analysis.

Dutta is eager to share his findings in hopes of finding collaborators and inspiring researchers and private industry to begin mining the data for other conditions. This is very low-hanging fruit, he said. Germline variants predicting outcome can be applicable to all types of diseases and not just cancer, and [they can predict] responsiveness to all types of therapy, and thats why Im particularly excited.

The researchers have published their findings in the scientific journal Genome Medicine. The studys authors were Chatrath, Roza Przanowska, Shashi Kiran, Zhangli Su, Shekhar Saha, Briana Wilson, Takaaki Tsunematsu,Ji-Hye Ahn, Kyung Yong Lee, Teressa Paulsen, Ewelina Sobierajska, Manjari Kiran, Xiwei Tang, Tianxi Li, Pankaj Kumar, Aakrosh Ratan and Dutta.

The research was supported by the National Institutes of Health, grants R01 CA166054, R01 1094 CA60499, T32 GM007267, AHA 18PRE33990261; and a Cancer 1095 Genomics Cloud Collaborative Support grant. The Seven Bridges Cancer 1096 Genomics Cloud has been funded by the National Cancer Institute, National Institutes of Health.

To keep up with the latest medical research news from UVA, subscribe to theMaking of Medicineblog.

Link:

UVA Finds Way to Improve Cancer Outcomes by Examining Patients' Genes - University of Virginia

Brown Alpert Medical School Autism Expert on Latest Advances in Research and Testing – GoLocalProv

Thursday, April 02, 2020

Smart Health on GoLocalProv

View Larger +

Moreno De Luca on GoLocal LIVE

"We know that autism is one of the mental health conditions that has the strongest genetic basis and that is because we know the chances of someone having autism are greater if there are other people with autism in their family," said Moreno De Luca.

"Many of the studies are showing us that theres hundreds if not thousands of individual rare genetic variants, that when we put them all together, are going to explain anywhere between 30 and 40% of cases of autism," he added. "So what this means in a nutshell and just the impact of this information is that potentially one out of every three people with autism are going to have an underlying genetic cause for their autism even if those individual genetic causes is going to be very rare."

"Our work focuses precisely on those rare genetic changes we want to identify what those individuals rare genetic variants are, to understand how they lead to clinical presentations like autism and to understand what other areas of mental health are impacted," said Moreno De Luca.

"Im very surprised to see more and more of the studies that are coming out to the point where science is moving so quickly what that means is most of our work is our ability to analyze the data that were acquiring and our ability to make sense of all that vast amount of data," he said. "I think things are moving extremely rapidly and Im very excited about whats coming in the next couple of years."

Path to Brown

Moreno De Luca, MD, MSc is a child, adolescent, and adult psychiatrist at the Verrecchia Clinic for Children with Autism and Developmental Disabilities at Bradley Hospital, where he also provides genetic psychiatry consultation to people with autism spectrum disorder, or neuropsychiatric conditions arising from a clinically-identifiable genetic cause.

I really knew I wanted to focus on both psychiatry and on genetics and I thought I had to pick between the two, said the Colombian native. It turns out theres an entire new field call psychiatric genetics and autism seems like the best opportunity to fuse those two interests together."

"I knew I wanted to do my clinical training here in the U.S. because of the great programs that are here and the clinical networks I came to Emory University for a postdoctoral fellowship in neurogenetics. From there I moved to Yale for my residency in adult psychiatry and finally I came here to Brown for my fellowship in Child and Adolescent psychiatry where I stayed on board as an attending psychiatrist at Bradley Hospital and an assistant professor at Brown University."

About Alpert Medical School -- and Smart Health

Since granting its first Doctor of Medicine degrees in 1975, the Warren Alpert Medical School has become a national leader in medical education and biomedical research. By attracting first-class physicians and researchers to Rhode Island over the past four decades, the Medical School and its seven affiliated teaching hospitals have radically improved the state's health care environment, from health care policy to patient care.

"Smart Health" is a GoLocalProv.com segment featuring experts from The Warren Alpert Medical School GoLocal LIVE.

Read the original post:

Brown Alpert Medical School Autism Expert on Latest Advances in Research and Testing - GoLocalProv

Coronavirus testing is ramping up. Here are the new tests and how they work. – Livescience.com

Getting tested for coronavirus in the U.S. has been difficult to impossible for many people, starting with technical difficulties with the kits initially developed by the Centers for Disease Control and Prevention (CDC) and continuing with shortages in swabs, reagents and other parts of test kits.

But despite these problems, private labs and companies are developing new tests to detect SARS-CoV-2, the virus that causes COVID-19. Some of these tests are designed to detect the virus without having to send samples to centralized laboratories. Others are blood tests that are meant to reveal whether someone has been exposed to the coronavirus in the past, even if they aren't currently sick.

The emerging array of tests can be hard to keep straight. Below, we break down the different types of tests and highlight some of the new tests that are slowly becoming available.

Related: Read live updates on the coronavirus

Most coronavirus testing discussed by public officials and the media refers to polymerase chain reaction testing, better known as PCR. These tests start with a nasopharyngeal swab, or a swab that goes up the nose far back into the throat. This swab collects mucous, saliva, bits of cells and if present viral RNA. The samples are then sent to a lab, where researchers apply chemicals to remove everything but the RNA. Enzymes are then added to transcribe the RNA into DNA. Next, this DNA is put into a real-time PCR (RT-PCR) machine along with another set of chemicals. The RT-PCR machine heats and cools the samples in a process that essentially Xeroxes the DNA, making thousands of copies of any genetic material in the samples.

Scientists then use sets of DNA fragments that complement fragments found in the coronavirus. If any viral genetic material is present, these fragments will bind to it. Chemical markers attached to the DNA release fluorescence when this DNA binding occurs. It's these flashes of fluorescence that scientists use to determine whether the virus is present in a sample.

The CDC's original failed test for the coronavirus was a PCR test. It did successfully detect SARS-CoV-2, said David Kroll, a professor of pharmacology at the University of Colorado Anschutz Medical Campus. But one of the chemicals used in the test also responded to non-coronavirus genetic material as if the virus were present returning false positive results. After this failure, the Food and Drug Administration issued Emergency Use Authorizations for private labs and hospitals to develop their own coronavirus PCR tests. These tests still have to meet the CDC's bar for accuracy, but they don't have to go through the long process of typical FDA approval. As of March 30, 20 emergency authorizations had been granted for different tests. The up-to-date list is on the FDA website.

These privately developed tests differ slightly from one another. They may home in on different regions of the coronavirus genome, for example. And some are made to work with a specific company's RT-PCR equipment, said Dr. Bobbi Pritt, a pathologist and microbiologist at the Mayo Clinic in Rochester, Minnesota. But these technical differences don't change how the tests function.

"They're all detecting the viral genetic material," Pritt told Live Science.

Large companies are ramping up production of coronavirus tests. For instance, Roche's test was given emergency authorization on March 13, and Stat News reported that the company could produce 400,000 tests a week. Likewise, Thermo Fisher Scientific plans to produce 5 million tests by April 3.

Typically, a RT-PCR tests take just a few hours to complete, according to ThermoFisher Scientific. But transporting samples to central labs takes time, as does preparing the samples to run. There have been reports of people waiting a week or more for test results as labs inundated with samples struggle to keep up.

The other limit to RT-PCR is that it detects only active infections. If someone has previously contracted the coronavirus and has recovered, RT-PCR won't detect it.

Some companies are rolling out point-of-care tests, which are tests that can be done entirely within clinics or doctors' offices or even in the parking lot of a mobile drive-through testing site.

These tests can be helpful for letting medical professionals know right away if a patient has COVID-19, which might save valuable hospital space and personal protective equipment (PPE). A negative test means that a person might be sent home without concern for infecting others, or treated by health care providers without gear such as N95 masks. Quick testing might also help a sick doctor or nurse know whether they must self-isolate for 14 days or whether they can return to the front lines more quickly, Pritt said.

Point-of-care tests can use PCR or other methods of quickly copying the genetic material in a sample so that any viral genes are detectable. Regardless of the precise reactions used, these tests require a proprietary piece of equipment, usually around the size of a toaster, and a set of one-time-use cartridges that contain all the chemicals needed for the procedure. The patient gives a sample, usually via a nasopharyngeal swab, which is inserted into the cartridge. The cartridge goes into the testing device, which heats and cools it to facilitate the proper chemical reactions. The results come back in less than an hour.

Similar technology is already used for rapid testing for other viruses, such as influenza, said Laura Dullanty, the marketing manager for Mesa Biotech, a San Diego-based company that received emergency-use authorization from the FDA for a new 30-minute coronavirus test on March 24. Developing the test, which is PCR-based, wasn't a huge technical challenge, said Melissa Obtera, a scientist and project manager at the company. The company used the CDC's chemical primers as a starting point, along with the equipment it already has for flu and RSV (a respiratory virus most common in babies and toddlers).

Related: How does the new coronavirus compare with the flu?

The real challenge, Obtera told Live Science, will be producing the cartridges and testing systems quickly. The company must practice social distancing on the manufacturing lines to keep workers from falling ill. Nonetheless, Dullanty said, the company is currently working with several county health departments and hospital systems to get the tests into use.

Meanwhile, Illinois-based medical technology company Abbott announced that it had emergency-use authorization to ship its rapid coronavirus tests starting this week. The test can return positive results in 5 minutes and rule out the coronavirus in 13 minutes, according to a news release. It uses a set of proteins to amplify viral genetic material without the temperature changes needed in traditional PCR. The company plans to start shipping 50,000 tests a day by April 1.

Cepheid, a California-based biotech company, has also received emergency authorization for its point-of-care PCR coronavirus test, Live Science previously reported. The test can return results in 45 minutes, according to Cepheid. The company begins shipping the tests this week.

While the point-of-care tests have benefits, they likely won't be a major factor in increasing overall testing rates, Kroll said. Abbott's test, for example, can run a sample in 5 minutes, but that's only one sample. Traditional PCR machines at central labs may take a few hours, but a machine can run large numbers of tests at a time. Many use standard 96-well plates, so they can run 96 samples at once. Thus, a point-of-care test might be able to provide quicker answers to individual patients, but they can]t handle the large numbers of tests needed to get a clearer picture of the pandemic.

Beyond detecting active infections, getting a handle on the pandemic will require tests that can detect anyone who has ever been exposed to SARS-CoV-2 even if they fought it off without showing symptoms. These tests, called serological tests, search the blood for antibodies to the virus.

Knowing who has already been infected is important for three reasons, Kroll said. One, health care workers who have been exposed and likely have immunity can go to work with less fear, and perhaps use less PPE than those who have not been exposed. That could help ease the strain on scarce PPE supplies, Kroll told Live Science. In addition, by testing the general population, individuals may be able to ease their social-distancing routine and even go back to work first once stay-at-home orders ease. Finally, those who have been sick might be able to help cure those who are severely ill.

"Serology could potentially be used to identify people who have protective immunity that could help other people," Pritt said.

It's called convalescent plasma treatment, and it works on a simple principle: Those who have fought off the infection have antibodies in their blood that helps the immune system take down SARS-CoV-2. These antibodies can be isolated from the blood of recovered patients and then injected into patients who are ill. The hope is that the antibodies will start stimulating the sick patients' immune systems to better fight the disease. This treatment is now being tested in New York City.

The CDC has been developing two serological tests for coronavirus for weeks, Stat News reported. On March 18, virologist Florian Krammer of the Icahn School of Medicine at Mount Sinai and colleagues posted a preprint paper describing their serological test, which they are now working to get into clinical use. The Krammer lab has set up a website describing their ingredients and techniques for any other lab that would like to use them. Researchers at the Mayo Clinic are developing serological tests as well, Pritt said.

There are also efforts to import already-developed serological tests from other countries. For example, the distributor Ideal Rehab Care Inc. has been approved to import a test from a Singapore-based manufacturer, according to the distributor's law firm.

Some companies are working on rapid serological tests that can be delivered at the point of care. SureScreen Diagnostics, for example has developed a testing strip to detect antibodies to the coronavirus in the blood; it works a bit like an at-home pregnancy test, with a paper readout and a colored line to indicate infection. The company touts the test as a way to work around the shortage of the swabs needed for PCR-based tests. But rapid antibody testing likely won't help detect cases early, Pritt said, as it typically takes around 8 days for the body to mount an antibody response to the virus. Serological testing may be useful in some cases where someone has been sick for more than 8 days without access to a test for active infections, she said.

"When you get into serology, it's more of these potential uses that we're still learning a lot about," Pritt said.

As coronavirus has shown itself to be widespread in the U.S., there has been some debate over the value of testing versus assuming anyone with symptoms has COVID-19, Kroll said. But even with widespread community transmission, testing can help track the disease, especially as it penetrates into lesser-hit regions.

"It's too serious of a disease to back off on testing," he said.

Originally published on Live Science.

ABCmouse - 1 Month Free!

The one-month trial gives you access to all of the educational site's 9,000 activities in reading, science, math and art. Keep your child busy and learning while we are all stuck indoors.View Deal

Here is the original post:

Coronavirus testing is ramping up. Here are the new tests and how they work. - Livescience.com

Muscular Dystrophy Association Announces Formation of Strategic Medical Advisory Team of Experts in Neuromuscular Care and Research – PRNewswire

NEW YORK, April 2, 2020 /PRNewswire/ --The Muscular Dystrophy Association (MDA) announced today the formation of its formal Medical Advisory Team who provide MDA with strategic guidance on issues that impact research and clinical care for people living with muscular dystrophy, amyotrophic lateral sclerosis (ALS) and related neuromuscular disorders more than 43 diseases. Each of the team members is a leading clinician at an MDA Care Center and is an internationally known expert in muscular dystrophy, ALS and related neuromuscular diseases. The MDA Care Center network spans over 150 locations at the nation's top medical institutions.

"We believe that engaging this team of world-class experts across neuromuscular diseases will enable MDA to lead the way in speeding the development of groundbreaking therapies and treatment paradigms that will transform the lives of those we serve," says Lynn O'Connor Vos, President and CEO of MDA. "These physicians are pillars of the neuromuscular disease community, each with focused expertise in specific diseases. Together, they will provide critical advice to MDA on our innovations in science and care programs and help ensure that we are making the maximum impact as the landscape of neuromuscular research, care and treatments evolve."

MDA's medical advisors will help lead the effort, along with more than 2,000 health care providers, to establish new clinical trials geared toward integration of MDA's innovative MOVR technology hub, which allows clinicians and researchers to share a wealth of disease-related information, establish professional protocols, and accelerate innovation.

Tonight, Dr. Barry Byrne, who will serve as chief medical advisor for the team, is joining MDA's EVP, Chief Advocacy & Care Services Officer, Kristin Stephenson for an MDA Facebook Live conversation about the precautions and best practices needed to protect the neuromuscular community in light of COVID-19. The event, scheduled for Thursday, April 2 from 6:00 to 6:30 pm EDT is accessible at https://www.facebook.com/MDAOrg/. The recording will be available for viewing after the event on MDA's COVID-19 resource page. The conversation will feature a live Q&A answering questions from people living with muscular dystrophy, ALS and related neuromuscular diseases including MDA families, and aims to provide the answers to questions regarding care duringthese uncertain times, and will cover topics related to preparedness, community impact, telemedicine and MDA's Care Center network of over 150 multidisciplinary care teams at top medical institutions nationwide.

Barry J. Byrne, MD, PhD, is an ardent supporter of newborn screening and has been an innovator and early adopter of new FDA-approved therapies that have the potential to alter the course of some neuromuscular disorders. He was the first physician to administer an approved gene therapy to a neuromuscular patient in the U.S.

"We are just beginning to realize the impact of the current revolution in the treatment of neuromuscular disorders. Newborn screening and access to newly-approved therapies are changing patients' lives when diagnosed with neuromuscular diseases; the MDA Care Center network is ready to provide these innovative treatments," says Dr. Byrne. "Disease-modifying therapies are no longer a thing of the future. There is an urgent need to bring innovative care, cutting-edge clinical research and new breakthrough treatments to the community."

Dr. Byrne will continue in his role as the associate chair of pediatrics and director of the Powell Gene Therapy Center at the University of Florida College of Medicine as he assumes this new position. He is also director of the MDA Care Center at the University of Florida.

Matthew B Harms, MD, will serve as a medical expert on ALS and other neuromuscular disorders. He is active in clinical research. Dr. Harms is associate professor of neurology at Columbia University's Vagelos College of Physicians and Surgeonsand serves at MDA's ALS Care Center at Columbia University. Dr. Harms received MDA's Diamond Award for his work directing an international effort with whole genome and transcriptome sequencing to bring precision medicine to ALS treatments.

John W. Day, MD, PhD, completes the Medical Advisory Team. Dr. Day is professor of neurology and pediatrics and director, Division of Neuromuscular Medicine at Stanford University. He directs Stanford's MDA Care Centers, which uniquely integrate the Lucile Packard Children's Hospital Pediatric and Transitional Neuromuscular Clinic with the Stanford Hospital Neuroscience Health Center's Neuromuscular and ALS Research and Clinic.The comprehensive team of investigators and clinicians in the Stanford Neuromuscular Program have helped develop novel gene modification and gene replacement treatments for spinal muscular atrophy, muscular dystrophy and ALS, and have spearheaded development of centralized data hubs like MDA's MOVR for neuromuscular disease.

About Barry J. Byrne, MD, PhD

Dr. Byrne is a clinician scientist who is studying a variety of rare diseases with the specific goal of developing therapies for inherited muscle disease. As a pediatric cardiologist, his focus is on conditions that lead to skeletal muscle weakness and abnormalities in heart and respiratory function. His group has made significant contributions to the understanding and treatment of Pompe disease, a type of neuromuscular disorder caused by an excess of a type of sugar (glycogen) in certain muscles. The research team has pioneered the use of adeno-associated virus (AAV) mediated gene therapy to restore heart and skeletal muscle function in Duchenne muscular dystrophy, Pompe, Friedrich's ataxia and other neuromuscular diseases. His group at the Powell Center has also established a series of new methods for large-scale AAV manufacturing to enable access for a wide variety of conditions.

About Matthew B. Harms, MD

Dr. Harms' post-doctoral and faculty work in neurogenetics led to the discovery of genes for dominant spinal muscular atrophy and limb-girdle muscular dystrophy type 1D. He sees patients in the Eleanor and Lou Gehrig ALS Center, the Adult Muscular Dystrophy Association Clinic, the Pediatric Muscular Dystrophy Association Clinic, and until recently, the ALS Clinic of the Bronx VA Hospital. His laboratory straddles Columbia's Motor Neuron Center and the Institute for Genomic Medicine, with a focus on generating, integrating, and analyzing clinical, genomic and transcriptomic datasets for amyotrophic lateral sclerosis and other neurological disorders.

About John W. Day, MD, PhD

Dr. Day has combined his expertise in synaptic physiology, genetics and neuromuscular medicine to help define the molecular mechanisms underlying myotonic dystrophy and other muscular dystrophies, neuropathies and ataxias. Under his leadership, the Stanford Neuromuscular Program is dedicated to the elucidation and treatment of neuromuscular diseases, integrating clinical care and clinical research with Stanford's basic science and translational programs. All Stanford pediatric and adult neuromuscular patients are asked to participate in research and are followed over time with functional evaluations. The Stanford Neuromuscular Program mission aligns fully with the goals of the MDA: to diagnose, investigate and characterize neuromuscular disorders precisely and completely; to develop novel treatments for neuromuscular disease; to incorporate novel treatments into the comprehensive care of patients with neuromuscular disorders; to advocate and support patients and families affected by neuromuscular disease so they can live life as fully and independently as possible; and to train the next generation of experts in neuromuscular diagnosis, care and research.

About MDA

MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS, and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than$1 billionsince our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases. MDA's MOVR is the first and only data hub that aggregates clinical, genetic, and patient-reported data for multiple neuromuscular diseases to improve health outcomes and accelerate drug development. MDA supports the largest network of multidisciplinary clinics providing best in class care at more than 150 of the nation's top medical institutions. Our Resource Center serves the community with one-on-one specialized support, and we offer educational conferences, events, and materials for families and healthcare providers. Each year thousands of children and young adults learn vital life skills and gain independence at summer camp and through recreational programs, at no cost to families. For more information visitmda.org.

SOURCE Muscular Dystrophy Association

https://www.mda.org

Here is the original post:

Muscular Dystrophy Association Announces Formation of Strategic Medical Advisory Team of Experts in Neuromuscular Care and Research - PRNewswire

Modalis Obtains Access to Foundational CRISPR IP – BioSpace

TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Modalis Therapeutics Corporation (Modalis) today announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has obtained a license to certain intellectual property that is controlled by Editas Medicine. Modalis is utilizing its proprietary epigenetic gene modulation technology, CRISPR-GNDM (Guide Nucleotide Directed Modulation), to treat patients with serious genetic disorders. Additional details including financial terms of the agreement were not disclosed.

"Our goal is to create CRISPR based gene therapies for genetic disorders, most of which fall into the orphan disease category. There should be no disease that is ignored because of its small patient population, and our mission to develop disease modifying treatments for these diseases reflects our belief that Every Life Deserves Attention. We are proud to be the pioneer in CRISPR based gene modulation therapy, said Haru Morita, Chief Executive Officer of Modalis.

We are pleased to establish this license agreement with Modalis Therapeutics as their mission is aligned with our mission to make transformative medicines for people living with serious diseases of unmet clinical need. CRISPR technology has many uses and applications, and we are pleased to include Modalis in our expanding portfolio of licensees so the greatest number of patients may benefit in the future from transformative medicines, said Cynthia Collins, president and chief executive officer, Editas Medicine.

About Modalis

Modalis Therapeutics is developing precision genetic medicines through epigenetic gene modulation. Founded by Osamu Nureki and leading scientists in CRISPR gene editing from University of Tokyo, Modalis is pursuing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double-stranded DNA cleavage, gene editing or base editing. Modalis is focusing initially on genetic disorders caused by loss of gene regulation resulting in excess or insufficient protein production which includes more than 660 genes that are currently estimated to cause human disease due to haploinsufficiency. Headquartered in Tokyo with laboratories and facilities in Cambridge, Massachusetts, the company is backed by leading Japanese investors including Fast Track Initiative, SBI Investment, UTokyo-IPC, SMBC Venture Capital, and Mizuho Capital. For additional information, visit http://www.modalistx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005248/en/

See the original post here:

Modalis Obtains Access to Foundational CRISPR IP - BioSpace

Group behind NYC COVID-19 tent hospital is forcing medical workers to abide by anti-gay statement of faith – Metro Weekly

Mount Sinai President David Reich tours the field hospital set up by Samaritans Purse in Central Park Photo: Mount Sinai Hospital.

LGBTQ advocates are expressing concern after Samaritans Purse, a North Carolina-based humanitarian aid organization with an evangelical Christian bent, established a 68-bed tent hospital in Central Park to treat overflow patients from Mount Sinai Hospital who are experiencing respiratory distress due to COVID-19.

While the additional facility will lessen the burden on the main Mount Sinai Hospital, equality advocates say there appears to be a catch: all medical workers working at the facility have been asked to agree with a Statement of Faith, part of which expresses vehement opposition to homosexuality and variant gender identities.

Samaritans Purse is led by Franklin Graham, an evangelical preacher and the son of the famous televangelist Billy Graham. Franklin Graham has previously made disparaging comments about the LGBTQ community, and, critics claim, has a track record of attempting to use humanitarian missions to proselytize to desperate people seeking out food, medical care, or other services in the midst of manmade, epidemiological, or natural disasters.

According to the website for Samaritans Purse, the organization is specifically seeking Christianmedical staff to operate the Central Park extension.

Medical workers recruited by Samaritans Purse are expected to read and abide by the organizations Statement of Faith that regurgitates evangelical Christian doctrine, particularly with regard to human sexuality and the fixed, binary nature of gender.

See also: Christian radio host says COVID-19 pandemic will stop children from being brainwashed into normalizing sexual deviancy

One section reads: We believe Gods plan for human sexuality is to be expressed only within the context of marriage, that God created man and woman as unique biological persons made to complete each other. God instituted monogamous marriage between male and female as the foundation of the family and the basic structure of human society. For this reason, we believe that marriage is exclusively the union of one genetic male and one genetic female.

Its unclear how Samaritans Purse will ensure that medical staff are adhering to those principles or what adherence to those principles would look like in practice.

According to the Gothamist, a spokesperson for Mayor Bill de Blasio who praised the erection of the overflow tent hospital said that the hospital will operate as a Mount Sinai facility, and therefore must adhere to the hospitals policy prohibiting discrimination based on sexual orientation and gender identity (in compliance with both city and state nondiscrimination laws).

Ourrecord on human rights is clear; and we are confident that the joint effort by Mt. Sinai and Samaritans Purse will save New Yorkers lives while adhering to the values we hold dear by providing care to anyone who needs it, regardless of background, Jane Meyer, the spokesperson for City Hall, said in a statement.

But openly gay New York State Sen. Brad Hoylman (D-Manhattan) fired off a warning shot, indicating that he and others would be monitoring the situation closely to ensure that Samaritans Purse isnt turning away or refusing to treat patients whose sexuality, identity, or lifestyle choices (such as a someone who engages in extramarital sex, or an IV drug user) do not conform to the Christian ideal expressed by Samaritans Purse.

COVID-19 doesnt discriminate, and neither should Franklin Graham, Hoylman said, as reported by the New York Daily News. Its unacceptable that a New Yorker infected with COVID-19 could be subjected to discriminatory treatment from an organization whose leader calls us immoral and detestable.

Brad Hoylman (left) Photo: Facebook.

Sadly, beggars cant be choosers: New York needs every ventilator we can get, Hoylman added. But homophobic pastor Franklin Graham and his field hospital operation in Central Park must guarantee all LGBTQ patients with COVID-19 are treated with dignity and respect. Well be watching.

Hoylamn, working with civil rights attorney Roberta Kaplan best known for successfully arguing before the Supreme Court that a section of the Defense of Marriage Act was unconstitutional and that the federal government should recognize legal same-sex marriages has crafted a legal document for medical workers to sign when they are providing services in a place of public accommodation.

By signing, medical providers agree to abide by New York regulations prohibiting discrimination against patients based on a number of characteristics, including sexual orientation or gender identity.

For decades, Franklin Graham has traveled throughout the country preaching a gospel of bigotry and hate. Hes said advocacy for LGBTQ rights is immoral and that marriage equality is detestable. His organization supports those awful opinions and actively recruits volunteers who share them, Hoylman said in a press release. Graham and his volunteers are free to adhere to whatever bigoted beliefs theyd like. But when they come to New York they need to abide by our Human Rights Law, which ensures marginalized New Yorkers are not subject to discrimination.

We cant let a pandemic change New Yorks values, he added. New York City must require every doctor or volunteer working at Grahams Central Park field hospital along with anyone providing medical services in a place of public accommodation to sign a statement affirming their commitment to following New York Citys Human Rights Law.

See also: Federal court strikes down Trumps anti-LGBTQ health care rule allowing religious-based discrimination

Questions over whom Samaritans Purse medical staff will treat underscores a larger concern that LGBTQ advocates have been expressing for some time about a trend toward faith-based refusals, particularly as the Trump administration seeks to expand exemptions that would allow health care providers to refuse to perform certain procedures that purportedly conflict with their religious beliefs.

In a letter to Mount Sinai staff, Dr. Dennis Charney, the dean of Mount Sinais Icahn School of Medicine, and Dr. David Reich, the president and chief operating officer of the hospital who identifies as LGBTQ himself acknowledged concerns about Samaritans Purses policies and political positions, but effectively said that the hospital is accepting help from Samaritans Purse due to the severity of the pandemic and the importance of saving lives, reports Gay City News.

While we have strong differences of opinion with Samaritans Purse on this issue, this does not detract from our shared mission to save lives in our wonderfully multicultural and diverse city, Charney and Reich wrote. While many in this nation could have responded to calls for help, Samaritans Purse not only responded, but did so in a fashion that no other organization could accomplish so rapidly.

In response to a follow-up inquiry from Metro Weekly, a Mount Sinai spokesperson issued a statement clarifying that all health care workers at the field hospital respiratory care unit will adhere to Mount Sinais nondiscrimination policy.

In order to help address the overflow of patients in our hospitals, Samaritans Purse and The Mount Sinai Hospital are working together to establish a Field Hospital respiratory care unit which will be run as a part of Mount Sinai, spokesman Jason Kaplan said in the statement.

Inside a tent at the Samaritans Purse field hospital Photo: Mount Sinai Hospital.

As such, all workers will adhere to The Mount Sinai Hospital principles and guidelines when it comes to not discriminating against patients or staff based on actual or perceived race, creed, color, religion, national origin, sex, gender, gender expression, gender identity, age, disability, marital, partnership or parental status, sexual orientation, alien or citizenship status, veteran or military status, or any other characteristic protected by law, Kaplan added. In short, while our organizations may have differences of opinions, when it comes to COVID-19 we are fully united: we will care for everyone and no patients or staff will be discriminated against.

Ultimately, this virus kills people of every religious beliefs, ethnicity, gender identity and sexual orientation, he noted. New York has lost over 1,000 people already, and more are dying every day. Mount Sinai and Samaritans Purse are unified in our mission to provide the same world-class care to anyone and everyone who needs it. No questions asked. We are all focused on one thing saving lives.

A spokesperson for Samaritans Purse rejected claims that any LGBTQ patients seeking care might be turned away or denied care.

Samaritans Purse does not discriminate in who we help, and we have a decades-long track record that confirms just that. We do not make distinctions about an individuals religion, race, sexual orientation, or economic status, Kaitlyn Lahm, the assistant director of marketing and media relations at Samaritans Purse, said in a statement responding to a Metro Weekly inquiry.

Our doors at the Emergency Field Hospital in the East Meadow are going to be open to all New Yorkers who need our help. We are here to save life, which is precious in Gods sight and we do it all in Jesus Name. We are a Christian organization and we hire Christians who share our statement of faith. We have a common denominator of our faith in Jesus Christ and sharing that hope.

Dr. Reich visiting the Samaritans Purse field hospital Photo: Mount Sinai Hospital.

But Ross Murray, the senior director of the GLAAD Media Institute, penned an op-ed in response to the establishment of the field hospital, expressing concerns that medical providers recruited by Samaritans Purse could choose to deny treatment to LGBTQ patients if they believed it violated their religious beliefs.

He said he was not surprised to hear about the requirement for volunteers to abide by the Statement of Faith.

When Graham claimed Satan is behind LGBTQ rights and advocacy, it signaled his willingness to prevent LGBTQ people from receiving access to coronavirus treatment. He can direct doctors to deny medications to HIV-positive patients, leaving them further at-risk for coronavirus. He may tell his hospital that they must turn away transgender people who come to them in a medical emergency, Murray wrote.

As the CEO of a religious institution, Graham canlegally instruct his field hospital to turn away LGBTQ people with symptoms, leaving them on their own to find care elsewhere. Its terrible to think that he would issue such an order, but Graham has long fought for religious hospitals, or even individual staff members, to be able to do just that, he added.

During this unprecedented national crisis, Franklin Graham must go on record and clarify that he will not turn away or discriminate against LGBTQ people at his field hospital, and that he will repeal his discriminatory ban on LGBTQ staff members, Murray concluded. With COVID-19 disproportionately affecting LGBTQ Americans, our lives may very well depend on it.

Editors note: This story was updated to include additional responses from Samaritans Purse and Mount Sinai Hospital.

Read more:

Gay couple told to leave home because homosexuals are contaminated by COVID-19

Tiger Kings Joe Exotic files $94 million lawsuit claiming he was targeted for being gay

Idaho governor signs two bills that discriminate against the transgender community

As a free LGBTQ publication, Metro Weekly relies on advertising in order to bring you unique, high quality journalism, both online and in our weekly edition. The ongoing coronavirus pandemic has forced many of our incredible advertisers to temporarily close their doors to protect staff and customers, and so were asking you, our readers, to help support Metro Weekly during this trying period. We appreciate anything you can do, and please keep reading us on the website and our new Digital Edition, released every Thursday and available for online reading or download.

See the article here:

Group behind NYC COVID-19 tent hospital is forcing medical workers to abide by anti-gay statement of faith - Metro Weekly